UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~March~~June 3130, 2016

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 000-54905

CAPSTONE FINANCIAL GROUP, INC.
(Exact name of registrant as specified in its charter)

Nevada		46-0684479
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

8600 Transit Road, East Amherst, NY		14051
(Address of principal executive offices)		(Zip Code)

(866) 798-4478
(Registrant's telephone number, including area code)

Copies of Communications to:

Stradling Yocca Carlson & Rauth, P.C.

4365 Executive Drive

Suite 1500

San Diego, CA 92121

(858) 926-3000

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated filer

(Do not check if a smaller reporting company)

☐

Smaller reporting company

☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of Common Stock, $0.001 par value, outstanding as of ~~May~~August 1626, 2016 was 9495,~~364~~628,~~148~~854 shares.

CAPSTONE FINANCIAL GROUP, INC.

QUARTERLY REPORT FOR THE QUARTER ENDED

~~MARCH~~JUNE 3130, 2016

Index to Report on Form 10-Q

PART I	Financial Information	Page
Item 1.	Financial Statements (Unaudited)	41
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	2823
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	3832
Item 4.	Controls and Procedures	3833
PART II	Other Information
Item 1.	Legal Proceedings	4135
Item1A.	Risk Factors	4135
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	4235
Item 3.	Defaults Upon Senior Securities	4235
Item 4.	Mine Safety Disclosures	4235
Item 5.	Other Information	4236
Item 6.	Exhibits	4336

-3-

(table of contents)

PART I Financial Information

Item 1. Financial Statements

CAPSTONE FINANCIAL GROUP, INC.

INDEX TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

			PAGES
Unaudited Condensed Statements of Financial Condition as of March 31, 2016 and December 31, 2015			5
Unaudited Condensed Statements of Financial Condition as of June 30, 2016 and December 31, 2015			2
Unaudited Condensed Statements of Operations for the three months ended March 31, 2016 and 2015			6
Unaudited Condensed Statements of Operations for the three months and six months ended June 30, 2016 and 2015			3
Unaudited Condensed Statement of Stockholders’ Equity for the three months ended March 31, 2016			7
Unaudited Condensed Statement of Stockholders’ Equity for the six months ended June 30, 2016			4
Unaudited Condensed Statements of Cash Flows for the three months ended March 31, 2016 and 2015			8
Unaudited Condensed Statements of Cash Flows for the six months ended June 30, 2016 and 2015			5
Notes to Unaudited Condensed Financial Statements			86

-41-

(table of contents)

CAPSTONE FINANCIAL GROUP, INC.

UNAUDITED CONDENSED STATEMENTS OF FINANCIAL CONDITION

	March 31, 2016			December 31, 2015
	June 30, 2016			December 31, 2015
ASSETS
Financial instruments, at fair value	$	1110,~~280~~402,~~330~~624		$	13,161,718
Cash		~~323~~102,~~947~~282			136,849
Salary advance - related party		~~300~~200,000			—
Prepaid expense		381,~~322~~997			4,152
Furniture and equipment, net		11,~~998~~350			12,645
Deposits		63,930			63,930
Total assets		1110,~~983~~862,~~527~~183			13,379,294
LIABILITIES AND STOCKHOLDERS’ EQUITY
LIABILITIES
Accrued expenses	$	~~286~~304,~~698~~049		$	314,830
Accrued interest payable - related party		—			135
Short term advances payable - related party		29165,~~700~~257			49,600
Note payable - related party		—			68,416
Put and call option liability		~~608~~550,~~731~~544			619,122
Income taxes payable		63,~~602~~200			2,400
Deferred tax liability		43,~~047~~325,~~557~~544			4,552,107
Total liabilities		4,~~979~~348,~~288~~594			5,606,610
STOCKHOLDERS' EQUITY
Common stock, $0.001 par value, 2,000,000,000 shares authorized;
94,364,148 issued and outstanding as of March 31, 2016 and December 31, 2015, respectively		94,565			94,565
94,364,148 issued and outstanding as of June 30, 2016 and December 31, 2015, respectively		94,565			94,565
Common stock subscribed but not issued (789,473 shares)		600,000			—
Treasury stock, $0.001 par value, 200,500 shares		(219,426	)		(219,426	)
Additional paid in capital		1,176,633			1,176,633
Retained earnings		54,~~952~~861,~~467~~817			6,720,912
Total stockholders' equity		76,~~004~~513,~~239~~589			7,772,684
Total liabilities and stockholders' equity	$	1110,~~983~~862,~~527~~183		$	13,379,294

See Accompanying Notes to Unaudited Condensed Financial Statements.

-52-

(table of contents)

CAPSTONE FINANCIAL GROUP, INC.

UNAUDITED CONDENSED STATEMENTS OF OPERATIONS

	For the three months ended March 31,
	For the three months ended June 30,						For the six months ended June 30,
	2016			2015			2016			2015
Revenues
Services income	$	—		$	50,001		$	—		$	100,002
Other income		123,~~000~~600			—			15,600			—
Interest income – related party		—			7,~~446~~014			—			14,460
		12,000			57,447
		3,600			57,015			15,600			114,462
Expenses
Personnel		~~170~~180,~~908~~952			4348,~~387~~158			351,860			91,545
Professional fees		92443,~~602~~683			~~260~~340,~~998~~596			536,286			601,594
General and administrative		~~447~~825,~~941~~508			~~156~~151,~~708~~617			1,273,448			308,325
Interest expense – related party		~~345~~—			53,~~056~~468			345			8,524
		711,796			466,149
		1,450,143			543,839			2,161,939			1,009,988
Realized and Unrealized Gain (Loss) on Financial Instruments
Realized gain on financial instruments, net		1,302,000			1,460,160
Realized gain (loss) on financial instruments, net		449,823			(2,286,616	)		1,751,309			(826,456	)
Change in unrealized loss on financial instruments, net		(1,870,997	)		(1,460,160	)
Change in unrealized gain (loss) on financial instruments, net		(819,342	)		(395,876	)		(2,689,825	)		(1,856,036	)
Loss on financial instruments, net		(~~568~~369,~~997~~519	)		—(2,682,492	)		(938,516	)		(2,682,492	)
Net loss before income taxes		(1,~~268~~816,~~793~~062	)		(~~408~~3,~~702~~169,316	)		(3,084,855	)		(3,578,018	)
Income tax benefit		(~~500~~725,~~348~~412	)		—(1,443,046	)		(1,225,760	)		(1,443,046	)
Net loss	$	(~~768~~1,~~445~~090,650	)	$	(~~408~~1,~~702~~726,270	)	$	(1,859,095	)	$	(2,134,972	)
Net loss per share – basic and diluted	$	(0.01	)	$	(0.0002	)	$	(0.02	)	$	(0.02	)
Weighted average shares outstanding – basic
and diluted		94,364,148			94,~~564~~553,~~648~~659			93,364,148			94,559,123

See Accompanying Notes to Unaudited Condensed Financial Statements.

-63-

(table of contents)

CAPSTONE FINANCIAL GROUP, INC.

UNAUDITED CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY

								Additional			Retained			Total
					Common Stock						Additional						Total
	Common Shares				~~Treasury~~Subscribed			~~Paid in~~Treasury			~~Earnings~~Paid in			~~Stockholders’~~Retained			Stockholders’
	Shares		Amount		~~Stock~~Unissued			~~Capital~~Stock			~~(Deficit)~~Capital			~~Equity~~Earnings			Equity
Balance, January 1, 2016		94,364,148	$	94,565	$	~~(219,426~~—	)	$	1(219,~~176,633~~426	)	$	61,~~720~~176,~~912~~633		$	76,~~772~~720,~~684~~912		$	7,772,684
Net loss		—		—		—			—			~~(768,445~~—	)		(768,445	)		(768,445	)
Balance, March 31, 2016		94,364,148	$	94,565	$	(219,426	)	$	1,176,633		$	5,952,467		$	7,004,239
Balance March 31, 2016		94,364,148		94,565		—			(219,426	)		1,176,633			5,952,467			7,004,239
Common Stock subscribed but not issued (789,473 shares) see Note 6		—		—		600,000			—			—			—			600,000
Net loss		—		—		—			—			—			(1,090,650	)		(1,090,650	)
Balance, June 30, 2016		94,364,148	$	94,565	$	600,000		$	(219,426	)	$	1,176,633		$	4,861,817		$	6,513,589

See Accompanying Notes to Unaudited Condensed Financial Statements.

-74-

(table of contents)

CAPSTONE FINANCIAL GROUP, INC.

UNAUDITED CONDENSED STATEMENTS OF CASH FLOWS

	For the three months ended
	For the six months ended
	March 31,
	June 30,
	2016			2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(~~768~~1,~~445~~859,095	)	$	(~~408~~2,~~702~~134,972	)
Adjustments to reconcile net loss to net cash
provided by operating activities:
Proceeds from sale of financial instruments		1,~~302~~752,000			~~940~~2,~~160~~754,860
Net change in unrealized gain on financial instruments		12,~~870~~689,~~997~~825			1,~~460~~856,~~160~~036
Net realized gain on financial instruments		(1,302,000	)		(1,460,160	)
Net realized (loss) gain on financial instruments		(1,751,309	)		826,456
Depreciation		~~647~~1,295			~~500~~1,000
(Increase) decrease in assets:
Note receivable		—			(7400,~~445~~000	)
Salary advance - related party		(300,000	)		—
Accrued interest receivable – related party		—			(14,459	)
Prepaid expense		830			86,209
Salary advance - related party		(200,000	)		—
Prepaid expense		(77,845	)		65,282
Deposits		—			(20,000	)
Increase (decrease) in liabilities:
Accrued taxes payable		~~4,202~~800			—201,607
Accrued expenses		(2810,~~132~~781	)		(59,~~109~~273	)
Accrued interest payable – related party		(135	)		58,~~055~~523
Deferred revenue		—			(50100,~~001~~002	)
Deferred tax liability		(~~504~~1,~~550~~226,563	)		—(1,644,653	)
Net cash provided by operating activities		275,414			560,667
Net cash (used in) provided by operating activities		(681,808	)		2,208,951
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of furniture and equipment		—			(2,039	)
Net cash used in investing activities		—			(2,039	)
CASH FLOWS FROM FINANCING ACTIVITIES
Net repayments on short term advances – related party		~~(19~~115,~~900~~657	)		—(9,175	)
Net repayments on notes payable – related party		(68,416	)		(~~450~~650,000	)
Net cash used in financing activities		(88,316	)		(450,000	)
Common stock subscribed – unissued		600,000			—
Net increase in cash		187,098			110,667
Net cash provided by (used in) financing activities		647,241			(659,175	)
Net (decrease) increase in cash		(34,567	)		1,547,737
Cash at beginning of period		136,849			12,685
Cash at end of period	$	~~323~~102,~~947~~282		$	~~123~~1,~~352~~560,422
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Interest paid	$	480		$	—
Noncash purchase of treasury stock	$	—		$	218,411

See Accompanying Notes to Unaudited Condensed Financial Statements.

-85-

(table of contents)

CAPSTONE FINANCIAL GROUP, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

Organization

~~The business focus of~~ Capstone Financial Group, Inc. (the "Company") is toa ~~invest~~diversified incompany ~~stock~~whose ofprimary ~~other~~business ~~companies.~~focuses ~~The~~going ~~Company~~forward ~~seeks~~include (a) to ~~discover,~~invest ~~unlock and grow value~~ in ~~privately-held~~stock orof ~~illiquid~~other companies, ~~including~~(b) ~~through~~to identify, ~~the~~pursue ~~exercise~~and ofcapitalize ~~influence~~on atopportunities ~~a company~~ in ~~support~~the ofminerals ~~operational improvements~~ and ~~strategic~~agricultural ~~initiatives.~~commodities Inindustries ~~some~~and ~~cases,~~(c) ~~the~~overseas ~~Company might be one of the largest shareholders of the other company~~commercial lending.

~~The~~Until ~~Company~~the ~~seeks~~second toquarter ~~work~~of ~~with~~2016, the ~~management~~Company considered ~~and~~its ~~boards~~primary ofbusiness ~~the~~focus ~~other~~to ~~companies.~~be ~~While~~investing ~~the~~its ~~Company~~own ~~does~~capital ~~not~~to ~~manage~~acquire the ~~day-to-day~~outstanding ~~operations~~equity securities of ~~these~~other companies. The Company sought, ~~the~~and ~~Company~~ seeks to ~~maintain~~discover, aunlock ~~thorough understanding of operations~~ and ~~perform~~grow ~~continual~~value ~~evaluations~~in ofprivately-held ~~performance~~or ~~and~~illiquid ~~prospects on an ongoing basis~~companies.

The Company sought, and seeks, to work with the management and boards of the other companies. While the Company does not manage the day-to-day operations of these companies, the Company sought, and seeks, to maintain a thorough understanding of operations and perform continual evaluations of performance and prospects on an ongoing basis.

The Company may also seek to actively trade in its strategic investment positions and/or enter into private securities transactions with regard to those positions, to capitalize on price fluctuations and realize profits or minimize losses.

The Company was incorporated on July 10, 2012 under the laws of the State of Nevada, as Creative App Solutions, Inc. On August 23, 2013, the Company amended its articles of incorporation and changed its name to Capstone Financial Group, Inc.

Market, Credit and Liquidity Risk

At ~~March~~June 3130, 2016 and December 31, 2015 the majority of Company’s investments are focused in one entity, Twinlab Consolidated Holdings, Inc. (“Twinlab”). Management believes that it will be able to liquidate a sufficient portion of its investment and/or raise additional capital to fund its obligations as and when they become due. However, no assurance can be given that market conditions in the future will continue to allow the Company to sell its investments in sufficient quantities to fund its obligations or to raise additional capital to do so.

Market risk is the potential loss the Company may incur as a result of changes in the market or fair value of a particular financial instrument. Risks arise in options and warrant contracts from changes in the market or fair value of their underlying financial instruments.

Credit risk is the potential loss the Company may incur as a result of the failure of a counterparty or an issuer to make payments according to the terms of a contract. Credit risk can arise from investment activities in financially distressed issuers. To manage this risk, the Company may seek to diversify its investment portfolio with respect to specific credits, sectors and asset classes.

The Company is also subject to market concentration risk since a significant portion of its investment portfolio has similar characteristics, and is therefore affected similarly by changes in economic conditions.

-96-

(table of contents)

CAPSTONE FINANCIAL GROUP, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Investments of the Company trade in thin markets and throughout the year, depending upon market conditions, may be considered inactive. As a result, the market values can be more volatile and difficult to determine relative to other securities. In addition, if the Company is required to liquidate all or a portion of its portfolio quickly, it may realize significantly less than the value at which it previously recorded its investments.

Basis of Presentation

The accompanying financial statements have been prepared using the accrual basis of accounting in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the accounting and financial reporting conventions of the investment company industry and in accordance with the instructions to Form 10-Q and Article 8 of Securities and Exchange Commission (“SEC”) Regulation S-X. Accordingly, they should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2015, included in the Company’s Annual Report on Form 10-K filed with the SEC on May 2, 2016. The unaudited condensed financial statements contain all normal recurring accruals and adjustments that in the opinion of management, are necessary to present fairly the financial position of the Company at ~~March~~June 3130, 2016, the results of the Company’s operations for the three months ~~period~~and six months periods ended ~~March~~June 3130, 2016 and the Company’s cash flows for the ~~three~~six months ended ~~March~~June 3130, 2016. The results of operations for the three months ~~period~~and ~~ended~~six ~~March~~months 31periods ended June 30, 2016 are not necessarily indicative of the results to be expected for the full year or any future interim periods.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash Equivalents

The Company considers any investments in short-term money market funds with original maturities of three months or less to be cash equivalents.

~~-10-~~Investments

Investments primarily comprise strategic, non-controlling equity ownership interests in privately held businesses or public companies with very illiquid trading markets. These strategic investments are accounted for at fair value as determined by internal valuation guidelines and/or outside appraisals as there are no readily ascertainable fair market value prices in accordance with the Financial Accounting Standards Board (~~table~~“FASB”) Accounting ofStandards ~~contents~~Codification (“ASC”) 946-10 and FASB ASC 820-10. Because the Company follows the financial accounting and reporting conventions of the investment company industry, it reports investments at estimated fair value.

-7-

CAPSTONE FINANCIAL GROUP, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

~~Investments~~FASB ASC 820-10-65-4 provides additional guidance for estimating fair value in accordance with FASB ASC 820-10 when the volume and level of market activity for the asset or liability have significantly decreased. FASB ASC 820-10-65-4 also includes guidance on identifying circumstances that indicate a transaction is not orderly. It acknowledges that in these circumstances quoted prices may not be determinative of fair value. FASB ASC 820-10-65-4 emphasizes that even if there has been a significant decrease in the volume and level of market activity for the asset or liability and regardless of the valuation technique(s) used, the objective of a fair value measurement remains the same. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction (that is, not a forced liquidation or distressed sale) between market participants at the measurement date under current market conditions. Under FASB ASC 820-10-65-4, quoted prices for assets or liabilities in inactive markets may require adjustment due to uncertainty as to whether the underlying transactions are orderly. There is little information, if any, to evaluate if individual transactions are orderly in an inactive market. Accordingly, the Company is required to evaluate the facts and circumstances to determine whether the transaction is orderly based on the weight of the evidence. FASB ASC 820-10-65-4 does not designate a specific method for adjusting a transaction or quoted price; however, it does provide guidance for determining how much weight to give a transaction or quoted price. Price quotes derived from transactions that are not orderly are not considered to be determinative of fair value and should be given less weight, if any, when estimating fair value. In the absence of observable market data at June 30, 2016 and December 31, 2015, the Company's fair value measurements included assumptions about future cash flow and appropriately risk-adjusted discount rates that it believes market participants would make in orderly market transactions.

Investments primarily comprise strategic, non-controlling equity ownership interests in privately held businesses or public companies with very illiquid trading markets. These strategic investments are accounted for at fair value as determined by internal valuation guidelines and/or outside appraisals as there are no readily ascertainable fair market value prices in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 946-10 and FASB ASC 820-10. Because the Company follows the financial accounting and reporting conventions of the investment company industry, it reports investments at estimated fair value.

FASB ASC 820-10-65-4 provides additional guidance for estimating fair value in accordance with FASB ASC 820-10 when the volume and level of market activity for the asset or liability have significantly decreased. FASB ASC 820-10-65-4 also includes guidance on identifying circumstances that indicate a transaction is not orderly. It acknowledges that in these circumstances quoted prices may not be determinative of fair value. FASB ASC 820-10-65-4 emphasizes that even if there has been a significant decrease in the volume and level of market activity for the asset or liability and regardless of the valuation technique(s) used, the objective of a fair value measurement remains the same. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction (that is, not a forced liquidation or distressed sale) between market participants at the measurement date under current market conditions. Under FASB ASC 820-10-65-4, quoted prices for assets or liabilities in inactive markets may require adjustment due to uncertainty as to whether the underlying transactions are orderly. There is little information, if any, to evaluate if individual transactions are orderly in an inactive market. Accordingly, the Company is required to evaluate the facts and circumstances to determine whether the transaction is orderly based on the weight of the evidence. FASB ASC 820-10-65-4 does not designate a specific method for adjusting a transaction or quoted price; however, it does provide guidance for determining how much weight to give a transaction or quoted price. Price quotes derived from transactions that are not orderly are not considered to be determinative of fair value and should be given less weight, if any, when estimating fair value. In the absence of observable market data at March 31, 2016 and December 31, 2015, the Company's fair value measurements included assumptions about future cash flow and appropriately risk-adjusted discount rates that it believes market participants would make in orderly market transactions.

Fair Value Measurements and Valuation Methodologies

GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a fair value hierarchy that prioritizes the use of inputs used in valuation methodologies into the following three levels:

~~-11-~~• Level 1: Inputs to the valuation methodology are quoted prices, unadjusted, for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and shall be used to measure fair value whenever available. • Level 2: Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets; inputs to the valuation methodology include quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs to the valuation methodology that are derived principally from or can be corroborated by observable market data by correlation or other means. • Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement. Level 3 assets and liabilities include financial instruments whose value is determined using discounted cash flow methodologies, as well as instruments for which the determination of fair value requires significant management judgment or estimation.

~~(table of contents)~~-8-

CAPSTONE FINANCIAL GROUP, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

• Level 1: Inputs to the valuation methodology are quoted prices, unadjusted, for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and shall be used to measure fair value whenever available.

• Level 2: Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets; inputs to the valuation methodology include quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs to the valuation methodology that are derived principally from or can be corroborated by observable market data by correlation or other means.

• Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement. Level 3 assets and liabilities include financial instruments whose value is determined using discounted cash flow methodologies, as well as instruments for which the determination of fair value requires significant management judgment or estimation.

The Company’s financial instruments are valued by level within the fair value hierarchy. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The valuation methodology for each investment type and discussion of key unobservable inputs is described below.

The Company often invests in common stocks that are thinly traded where the closing trading price is not considered to be a fair indication of the value for which the Company can sell or buy the common stock. In such cases, as in the case of private-company limited liability company membership interests held by the Company, the common stock must be analyzed to determine what exit price the Company would receive when liquidating the position. These positions are classified as Level 3 securities.

The significant unobservable inputs used in the fair value measurement of the Company’s Level 3 common stocks are growth rate, risk premium, revenue multiples and EBITDA multiples. Increases or decreases in any of those inputs in isolation would result in a lower or higher fair value measurement, respectively.

The Company has warrants and call options to purchase common stock in illiquid public companies. Generally, there is no established market for these investments. The Company values these warrants and call options by using a model that takes into consideration the exercise or call price of the warrant or call option, the price of the underlying common stock and the expiration date of the warrant or call option.

-12-

(table of contents)

CAPSTONE FINANCIAL GROUP, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

The significant unobservable inputs used in the fair value measurement of the Company’s warrants and call options includes the price of the underlying thinly traded common stock (determined based upon growth rate, risk premium, revenue multiples and EBITDA multiples), duration and discount rate and volatility. Increases or decreases in the premium-to-parity would result in a higher or lower fair value measurement, respectively.

Generally, when the Company invests in common stocks that are traded on the NASDAQ Markets or over-the-counter markets (such as the OTCBB, OTCQB or OTC Pink marketplaces), ~~such~~ such common stocks are valued at the last traded price. If there is no trade on a measurement date, the Company will typically ~~value~~ value the common stock at the closing bid price. However, in certain circumstances, the closing trading price is not considered to be a fair indication of the value for which the Company can sell the common stock. In such cases, the common stock must be analyzed to determine what exit price the Company would receive when liquidating the position. Investments in non-marketable common stocks at ~~March~~June 3130, 2016 and December 31, 2015 were valued based, in part, on subsequent transactions with unrelated third parties and at at December 31, 2015 were valued by the Company with the assistance of an independent valuation consultant. These positions are ~~classified~~ classified as Level 3 securities by the Company.

From time to time, the Company has investments in private limited liability companies. Generally, there is no established market for these investments. The Company values these interests by means of both quantitative and qualitative measures, generally including the financial stability of the company, the economic rights of the interests and the economic prospects of the company.

The significant unobservable input used in the fair value measurement of the Company’s limited liability company investments is the expected recovery of contributed capital. Increases or decreases in the expected recovery would result in a higher or lower fair value measurement, respectively. -9-

Derivative Financial Instruments

Derivative financial instruments include call options and warrants at March 31, 2016 and December 31, 2015. Derivatives are accounted for at fair value with changes in fair value reported in operations. The significant unobservable inputs used in the fair value measurement of the Company’s derivative financial instruments include the underlying common stock, duration, volatility and discount rate, which are used in the option pricing model. Changes to any of those inputs in isolation would result in fluctuations in the fair value measurement.

-13-

(table of contents)

CAPSTONE FINANCIAL GROUP, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Derivative Financial Instruments

Derivative financial instruments include call options and warrants at June 30, 2016 and December 31, 2015. Derivatives are accounted for at fair value with changes in fair value reported in operations. The significant unobservable inputs used in the fair value measurement of the Company’s derivative financial instruments include the underlying common stock, duration, volatility and discount rate, which are used in the option pricing model. Changes to any of those inputs in isolation would result in fluctuations in the fair value measurement.

Investment Transaction, Related Income and Expenses

Purchases and sales of investments are recorded on a trade-date basis. Realized gains and losses on investments are recognized on the first-in, first-out method. Dividend income on investments owned is recognized on the ex-dividend date, net of applicable withholding taxes.

Treasury Stock Purchases

The Company is authorized to ~~repurchase~~ repurchase shares of the Company’s common stock in private transactions from time to time. The Company records treasury stock purchases at cost. Any treasury stock removed from treasury is valued at cost using the average cost method.

Revenue Recognition

The Company recognizes revenue for services when all of the following conditions are satisfied: (1) there is persuasive evidence of an arrangement; (2) the related service has been provided to the customer; (3) the amount of fees to be paid by the customer is fixed or determinable; and (4) the collection of fees is probable.

Earnings per Share

~~The Company follows FASB ASC 260 for earnings per share.~~ Basic earnings per common share calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. As of ~~March~~June 3130, 2016 and 2015, there were no dilutive common shares equivalents outstanding.

~~Concentration Risks~~ -10-

During the quarter ended March 31, 2016, the Company had $12,000 of sublease income from two sublessees. During the quarter ended March 31, 2015, the Company had $50,001 in revenue generated from one customer for consulting services and had interest income from a related party of $7,446.

-14-

(table of contents)

CAPSTONE FINANCIAL GROUP, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Concentration Risks

During the quarter and six months ended June 30, 2016, the Company had $3,600 and $15,600, respectively, of sublease income from two sublessees. During the quarter and six months ended June 30, 2015, the Company had $50,001 and $100,002, respectively, in revenue generated from one customer for consulting services and had interest income from a related party of $7,014 and $14,460, respectively.

Income Taxes

~~The Company follows ASC Topic 740 for recording the provision for income taxes.~~ Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change.

Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse.

The Company applies a more-likely-than-not recognition threshold for all tax uncertainties. ASC Topic 740 allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the taxing authorities. As of ~~March~~June 3130, 2016 the Company reviewed its tax positions and determined there were no outstanding or retroactive tax provisions with less than a 50% likelihood of being sustained upon examination by the taxing authorities.

The Company is required to file Federal and New York and California state income tax returns. The Company’s tax return status will remain open until a tax return has been filed.

Advertising costs

Advertising costs are expensed as incurred. For the ~~quarters~~quarter and six months period ended ~~March~~June 3130, 2016, advertising costs of $330 and $15,215, respectively, were included in general and administrative expenses. For the quarter and six months period ended June 30, 2015, advertising costs of $1415,~~930~~120 and $2136,~~170~~290, respectively, were included in general and administrative expenses.

-1511-

(table of contents)

CAPSTONE FINANCIAL GROUP, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Recent Accounting Pronouncements

In May 2014, the FASB issued Accounting Standards update 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"). ASU 2014-09 specifies a comprehensive model to be used in accounting for revenue arising from contracts with customers, and supersedes most of the current revenue recognition guidance, including industry specific guidance. It applies to all contracts with customers except those that are specifically within the scope of other FASB topics, and certain of its provisions also apply to transfers of nonfinancial assets, including in-substance nonfinancial assets that are not an output of an entity's ordinary activities. The core principal of the model is that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the transferring entity expects to be entitled in exchange. To apply the revenue model, an entity will: 1) identify the contract(s) with a customer, 2) identify the performance obligations in the contract, 3) determine the transaction price, 4) allocate the transaction price to the performance obligations in the contract, and 5) recognize revenue when (or as) the entity satisfies a performance obligation. For public companies, ASU 2014-09 is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016. Early adoption is not permitted. Upon adoption, entities can choose to use either a full retrospective or modified approach, as outlined in ASU 2014-09. As compared with current GAAP, ASU 2014-09 requires significantly more disclosures about revenue recognition. The Company has not yet assessed the potential impact of ASU 2014-09 on the financial statements.

In May 2015, the FASB issued amended guidance on the disclosures for investments in certain equities that calculate net asset value per share (or its equivalent). The amendments remove the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The amendments also remove the requirement to make certain disclosures for all investments that are eligible to be measured at fair value using the net asset value per share practical expedient. Rather, those disclosures are limited to investments for which the entity has elected to measure the fair value using that practical expedient. The guidance is effective for fiscal years beginning after December 15, 2015 and for interim periods within those years. As of June 30, 2016, the Company does not own any investments in equities that calculate net asset value per share (or its equivalent).

In February 2016, the FASB issued Accounting Standards update 2016-02, Leases ("ASU 2016-02"). ASU 2016-02 requires a lessee to recognize a lease asset representing its right to use the underlying asset for the lease term, and a lease liability for the payments to be made to lessor, on its balance sheet for all operating leases greater than 12 months. ASU 2016-02 will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company has not yet adopted ASU 2016-02 nor assessed its potential impact on the financial statements.

-1612-

(table of contents)

CAPSTONE FINANCIAL GROUP, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

NOTE 3 – FAIR VALUE MEASUREMENTS

The Company'’s financial instruments recorded at fair value have been categorized based upon a fair value hierarchy in accordance with accounting guidance. The following fair value hierarchy tables set forth the Company’s recurring fair value measurements at ~~March~~June 3130, 2016 and December 31, 2015.

-17-

	Assets and Liabilities Measured at
	Fair Value on a Recurring Basis
	June 30, 2016
	Level 1		Level 2		Level 3		Total
Assets
Financial instruments, at fair value:
Common Stocks	$	—	$	—	$	8,149,214	$	8,149,214
Real Estate Company Investments		—		—		277,500		277,500
2014 Call Options		—		—		1,135,863		1,135,863
Series B Warrants		—		—		840,047		840,047
Total Financial instruments, at fair value		—		—		10,402,624		10,402,624
Total assets held at fair value	$	—	$	—	$	10,402,624	$	10,402,624

Liabilities
Financial instruments, at fair value:
Third Party Call Options		—		—		550,544		550,544
Total liabilities held at fair value	$	—	$	—	$	550,544	$	550,544

(table of contents)

CAPSTONE FINANCIAL GROUP, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

NOTE 3 – FAIR VALUE MEASUREMENTS (CONTINUED)

	Assets and Liabilities Measured at
	Fair Value on a Recurring Basis
	March 31, 2016
	Level 1		Level 2		Level 3		Total
Assets
Financial instruments, at fair value:
Common Stocks	$	—	$	—	$	8,598,030	$	8,598,030
Real Estate Company Investments		—		—		277,500		277,500
2014 Call Options		—		—		1,135,863		1,135,863
Series B Warrants		—		—		1,268,937		1,268,937
Total Financial instruments, at fair value		—		—		11,280,330		11,280,330
Total assets held at fair value	$	—	$	—	$	11,280,330	$	11,280,330
Liabilities
Financial instruments, at fair value:
Third Party Call Options		—		—		608,731		608,731
Total liabilities held at fair value	$	—	$	—	$	608,731	$	608,731

	Assets and Liabilities Measured at
	Fair Value on a Recurring Basis
	December 31, 2015
	Level 1		Level 2		Level 3		Total
Assets
Financial instruments, at fair value:
Common Stocks	$	—	$	—	$	9,896,605	$	9,896,605
Real Estate Company Investments		—		—		277,500		277,500
2014 Call Options		—		—		1,135,863		1,135,863
Series B Warrants		—		—		1,851,750		1,851,750
Total Financial instruments, at fair value		—		—		13,161,718		13,161,718
Total assets held at fair value	$	—	$	—	$	13,161,718	$	13,161,718

Liabilities
Financial instruments, at fair value:
Third Party Call Options		—		—		619,122		619,122
Total liabilities held at fair value	$	—	$	—	$	619,122	$	619,122

-1813-

(table of contents)

CAPSTONE FINANCIAL GROUP, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

NOTE 3 – FAIR VALUE MEASUREMENTS (CONTINUED)

This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. For some products or in certain market conditions, observable inputs used in valuing certain financial assets and liabilities were unavailable. In situations where there is little, if any, market activity for an asset or liability at the measurement date, the fair value measurement objective remains to measure the financial asset at the price that would be received by the holder of the financial asset (or liability) in an orderly transaction that is not a forced liquidation or distressed sale at the measurement date.

Details of the Company’s recurring fair value measurements are as follow:

March 31, 2016	Cost		Estimated Fair Value			Unrealized Gain (Loss)
June 30, 2016	Cost		Estimated Fair Value			Unrealized Gain (Loss)
ASSETS
Common Stocks	$	1,004,~~478~~300	$	8,~~598~~149,~~030~~214		$	7,~~593~~144,~~552~~914
Real Estate Company Investments		277,500		277,500			—
2014 Call Options		450		1,135,863			1,135,413
Series B Warrants		—		1840,~~268,937~~047			1840,~~268,937~~047
	$	1,282,~~428~~250	$	1110,~~280~~402,~~330~~624		$	9,~~997~~120,~~902~~374
LIABILITIES
Third-Party Call Options	$	—	$	(~~608~~550,~~731~~544	)	$	(~~608~~550,~~731~~544	)

December 31, 2015	Cost		Estimated Fair Value			Unrealized Gain (Loss)
ASSETS
Common Stocks	$	1,004,992	$	9,896,605		$	8,891,613
Real Estate Company Investments		277,500		277,500			—
2014 Call Options		450		1,135,863			1,135,413
Series B Warrants		—		1,851,750			1,851,750
	$	1,282,942	$	13,161,718		$	11,878,776

LIABILITIES
Third Party Call Options	$	—	$	(619,122	)	$	(619,122	)

~~-19-~~For the quarter ended June 30, 2016, the Company recorded a net change in unrealized gain/(loss) on financial instruments of $(819,342) and a net realized gain on financial instruments of $449,823. For the quarter ended June 30, 2015, the Company recorded a net change in unrealized gain on financial instruments of $(395,876) and a net realized loss on financial instruments of $2,286,616.

~~(table of contents)~~-14-

CAPSTONE FINANCIAL GROUP, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

NOTE 3 – FAIR VALUE MEASUREMENTS (CONTINUED)

For the ~~quarter~~six months period ended ~~March~~June 3130, 2016, the Company recorded a change in net unrealized ~~loss~~gain on financial instruments of $1(2,~~870~~689,~~997~~825) and a net realized gain on financial instruments of $1,~~302~~751,~~000~~309. For the ~~quarter~~six months period ended ~~March~~June 3130, 2015, the Company recorded a change in net unrealized gain/(loss) on financial instruments of $(1,~~460~~856,~~160~~036) and a net realized ~~gain~~loss on financial instruments of $1826,~~460,160~~456.

During the first quarter of 2014, the Company purchased shares in a company traded on the OTC Markets for a total of $2,919. The Company currently categorizes these holdings as Level 3 assets. As of ~~March~~June 3130, 2016, this investment is carried at $0 value under management’s valuation guidelines.

In August 2014, the Company purchased 10,987,500 split-adjusted shares of common stock of Twinlab in private transactions from 25 shareholders for total consideration of $3,296. In November 2014, the Company sold 436,681 of these shares.

In August 2014, the Company purchased options to acquire 8,743,000 outstanding shares of Twinlab’s Common Stock (collectively, the “Call Options”) in a private transaction from 14 stockholders, for total consideration of $2,623. The Call Options exercise price is $0.0001 per share and the Call Options expired in August 2015. Such options were immediately exercisable and in February 2015, the Company exercised 7,244,500 of those options. As of ~~March~~June 3130, 2016, the Company owns 1,498,500 of these options to acquire shares of Twinlab’s Common Stock.

In September 2014, Twinlab issued to the Company a Series A Warrant to purchase up to 52,631,579 shares of Twinlab’s Common Stock at an exercise price of $0.76 per share (the “Series A Warrant”) and a Series B Warrant to purchase up to 22,368,421 shares of Twinlab’s Common Stock at an exercise price of $0.76 per share (the “Series B Warrant”). Both the Series A Warrant and the Series B Warrant were exercisable from October 2014 through October 2017.

Twinlab and the Company also entered into a Common Stock Put Agreement, dated as of September 30, 2014, as amended on December 15, 2014 (the “Put Agreement”). Pursuant to the Put Agreement, if the Company did not exercise the Series A Warrant by February 16, 2015 and thereafter at a rate of no less than 1,461,988 shares of Common Stock (“the Minimum Amount”) per month (the “Minimum Rate”) over the term of the Series A Warrant, Twinlab had the right (subject to certain conditions) to require the Company to exercise the Series A Warrant at the Minimum Rate for the duration of the Series A Warrant.

In 2015, the Company sold an aggregate of 3,976,647 units of Twinlab securities to various unrelated third party accredited investors. Each unit consisted of one share of (unrestricted) Twinlab common stock and a detachable call option to purchase from the Company, for $1.00 per share, one (restricted) share of Twinlab common stock. The term of each such call option was three years from the respective unit sale date and the call option was valued at $0.156 per call option.

~~-20-~~In addition, in 2015, the Company sold an aggregate of 2,078,255 shares of Twinlab common stock (without any associated detachable call options) to various unrelated third party accredited investors, for $0.76 per share.

~~(table of contents)~~-15-

CAPSTONE FINANCIAL GROUP, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

NOTE 3 – FAIR VALUE MEASUREMENTS (CONTINUED)

In addition, in ~~2015~~the first quarter of 2016, the Company sold an aggregate of 21,~~078~~713,~~255~~159 shares of Twinlab common stock (without any associated detachable call options) to various unrelated third party accredited investors, for $0.76 per share. In the second quarter of 2016, the Company sold an aggregate of 592,106 shares of Twinlab common stock (without any associated detachable call options) to various unrelated third party accredited investors, for $0.76 per share. As of June 30, 2016, the Company owned 10,750,942 shares of Twinlab’s common stock.

InTwinlab ~~addition,~~and in the ~~first~~Company ~~quarter~~entered into a Compromise Agreement and Release and an Amendment No. 1 to Series B Warrant, each dated as of ~~2016~~May 28, 2015, pursuant to which, among other things: (a) the Company ~~sold~~surrendered anthe ~~aggregate~~entire remaining-unexercised portion of 1the Series A Warrant (51,~~713~~973,~~159~~684 ~~shares~~warrants) and 4,368,421 of ~~Twinlab~~the ~~common~~warrants ~~stock~~under the Series B Warrant; (~~without~~b) ~~any~~the Put Agreement was terminated; (c) the remaining 18,000,000 warrants under the Series B Warrant were deemed divided into four tranches, each with an associated date ~~detachable~~beyond ~~call~~which it would no longer be exercisable: one tranche for 2,000,000 warrant shares (no longer exercisable after November 30, ~~options~~2015; such tranche of warrants expired mostly unexercised), toone ~~various~~for ~~unrelated~~4,000,000 ~~third~~warrant ~~party~~shares ~~accredited~~(expired ~~investors~~on March 31, 2016), one for 6,000,000 warrant shares (no longer exercisable after July 31, 2016) and another for 6,000,000 warrant shares (no longer exercisable after November 30, 2016); and (d) the Company granted Twinlab three contingent call options, at $0.7601 per share, to acquire Twinlab shares from the Company to the extent that upon effective expiration of the second, third and fourth tranches the Company had not exercised the warrants within such tranches (the “Contingent Call Options”). AsThe three Contingent Call Options would be for a number of ~~March~~Twinlab 31shares equal to 25% of such unexercised warrants (i.e., ~~2016~~a maximum of 1,000,000 shares if the Company exercised ~~owns~~no warrants from the second tranche, a maximum of 1,500,000 shares if the Company exercised no warrants from the third 11tranche and a maximum of 1,~~343~~500,~~048~~000 shares if the Company exercised no warrants from the fourth tranche). In addition, Twinlab could not exercise a Contingent Call Option unless it had satisfied such option’s “Liquidity Condition,” namely that for each of the three or four months before the tranche’s effective expiration date Twinlab must have a financial position sufficient to show a 1.15x fixed charge coverage ratio for a certain trailing period, all as defined by Twinlab’s ~~Common~~Credit and ~~Stock~~Security Agreement dated January 22, 2015. Twinlab also agreed in the Compromise Agreement and Release that, given that the Company has identified, and may in the future identify, to Twinlab on a confidential basis persons to whom the Company might sell the Company’s Twinlab shares, Twinlab shall not, without the Company’s prior written consent, privately place Twinlab equity securities to any persons theretofore or thereafter first introduced to Twinlab by the Company; provided that Twinlab may, without the Company’s consent, privately place Twinlab equity securities to such a person at any time after the earlier of (a) the date the entire Series B Warrant has expired and/or been exercised, or (b) the first anniversary of such particular introduction. As of June 30, 2016, the Company held 12,000,000 warrants under the Series B Warrant.

~~Twinlab~~On ~~and~~October ~~the Company entered into a Compromise Agreement and Release and an Amendment No.~~ 1 ~~to Series B Warrant~~, ~~each dated as of May 28,~~ 2015, ~~pursuant~~ toTwinlab ~~which, among other things: (a) the Company surrendered the entire remaining-unexercised portion of the Series A Warrant (51,973,684 warrants)~~ and ~~4,368,421 of~~ the ~~warrants under the Series B Warrant; (b) the Put~~ ~~Agreement~~Company ~~was~~entered ~~terminated; (c) the remaining 18,000,000 warrants under the Series B Warrant were deemed divided~~ into ~~four tranches,~~Amendment each with an associated date beyond which it would no longer be exercisable: one tranche for 2,000,000 warrant shares (no longer exercisable after November 30, 2015; such tranche of warrants expired mostly unexercised), one for 4,000,000 warrant shares (expired on March 31, 2016), one for 6,000,000 warrant shares (no longer exercisable after July 31, 2016) and another for 6,000,000 warrant shares (no longer exercisable after November 30, 2016); and (d) the Company granted Twinlab three contingent call options, at $0No.01 ~~per~~1 ~~share,~~ to ~~acquire~~Agreement Twinlab shares from the Company to the extent that upon effective expiration of the second, third and fourth tranches the Company had not exercised the warrants within such tranches (the “Contingent Call Options”). The three Contingent Call Options would be for aLimited ~~number~~Waiver of ~~Twinlab shares~~Non-Circumvention ~~equal~~Provision to 25% of such unexercised warrants (i.e., a maximum of 1,000,000 shares if the Company exercised no warrants from the second tranche, a maximum of 1,500,000 shares if the Company exercised no warrants from the third tranche and a maximum of 1,500,000 shares if the Company exercised no warrants from the fourth tranche). In addition, Twinlab could not exercise a Contingent Call Option unless it had satisfied such option’s “Liquidity Condition,” namely that for each of the three or four months before the tranche’s effective expiration date Twinlab must have a financial position sufficient to ~~show a 1.15x fixed charge coverage ratio for a certain trailing period, all as defined by Twinlab’s Credit and Security Agreement dated January 22, 2015. Twinlab also agreed in the~~ Compromise Agreement and Release ~~that~~, ~~given~~pursuant ~~that the Company has identified, and may in the future identify,~~ to ~~Twinlab~~which on a ~~confidential~~prior ~~basis persons~~agreement tocalling ~~whom~~for ~~the~~contingent ~~Company~~payments ~~might~~of ~~sell~~cash ~~the~~and ~~Company’s Twinlab shares, Twinlab shall not, without the Company’s prior written consent, privately place Twinlab~~ equity ~~securities~~ to ~~any persons theretofore or thereafter first introduced to Twinlab by~~ the Company; ~~provided~~was ~~that~~amended to ~~Twinlab~~remove ~~may, without~~ the Company’s ~~consent,~~right ~~privately place Twinlab equity securities~~ to ~~such a person at~~ any ~~time~~such ~~after~~contingent ~~the~~payments ~~earlier~~ of ~~(a)~~cash ~~the~~and ~~date~~equity ~~the~~compensation, ~~entire Series B Warrant has expired~~ and~~/or been~~ ~~exercised,~~in orreturn ~~(b)~~ the ~~first~~three ~~anniversary~~Contingent Call ofOptions ~~such~~were ~~particular introduction. As of~~ immediately ~~after the close of business on March 31, 2016, the Company held 12,000,000 warrants under the Series B Warrant~~cancelled.

-2116-

(table of contents)

CAPSTONE FINANCIAL GROUP, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

NOTE 3 – FAIR VALUE MEASUREMENTS (CONTINUED)

OnAs ~~October~~of 1,June ~~2015~~30, ~~Twinlab and the Company entered into Amendment No. 1 to Agreement for Limited Waiver of Non-Circumvention Provision and to Compromise Agreement and Release~~2016, ~~pursuant~~ ~~to which a prior agreement calling for contingent payments of cash and equity to~~ the Company ~~was amended to remove the Company~~’s ~~right~~position in toTwinlab ~~any~~securities ~~such~~was ~~contingent~~as ~~payments of cash and equity compensation~~follows, and ~~in return~~ the ~~three~~Company ~~Contingent~~had ~~Call Options~~no ~~were~~contingent ~~immediately~~liabilities ~~cancelled.~~to Twinlab:

As- ofThe ~~March~~Company held 10,750,942 outstanding Twinlab shares (9,764,100 unrestricted, free-trading Twinlab shares and 986,842 restricted Twinlab shares). - The Company held 12,000,000 warrants under the Series B Warrant, at a $0.76 per share exercise price, with effective expiration dates at July 31, 2016 (as to 6,000,000 of such warrants) and November 30, 2016 (as to the ~~Company~~other ~~owned less~~6,000,000 ~~than~~of ~~10%~~such warrants). - A Registration Rights Agreement remains in full force and effect to enable the Securities Act registration of all Twinlab shares issued upon prior or future exercises of the Company’s ~~outstanding~~Warrants. ~~common~~- ~~stock~~The Company has a claim against third-party optionors for delivery to the Company of 1,498,500 Twinlab shares against the Call Options which they granted to the Company and which the Company has exercised. - The Company is contingently obligated to deliver Twinlab shares to its accredited-investor counterparties under the 3,976,647 detachable call options, if and when the detachable call options are exercised. - The Company has no actual or potential Put liability or Contingent Call Option liability.

InAs ~~July 2015,~~of inJune ~~exchange for $277~~30,~~500, the~~ ~~Company acquired a 20% interest in privately-held Western New York real estate companies LC Strategic Realty~~2016, ~~LLC~~ ~~and LC Strategic Holdings, LLC, as well as in all other business conducted or to be conducted by~~ the ~~firms’~~Company ~~majority holders~~owned toless ~~the~~than ~~extent~~10% ~~such other business has a primary focus on (a) real estate (subject to the exclusion~~ of ~~certain~~Twinlab’s ~~specified projects),~~outstanding ~~(b) media/entertainment/show~~common ~~business, or (c) endorsements/advertisements/personal appearances/use of likeness/monetization of celebrity~~stock.

-2217-

(table of contents)

CAPSTONE FINANCIAL GROUP, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

NOTE 3 – FAIR VALUE MEASUREMENTS (CONTINUED)

~~The~~In ~~following~~July 2015, ~~table~~in ~~includes~~exchange for $277,500, the Company acquired a ~~roll~~20% interest in privately-held Western New York real estate companies LC Strategic Realty, LLC and ~~forward~~LC ofStrategic Holdings, LLC, as well as in all other business conducted or to be conducted by the ~~amounts~~firms’ ~~for~~majority holders to the ~~quarter~~extent ~~ended~~such ~~March~~other ~~31,~~business ~~2016~~has ~~for~~a ~~financial~~primary ~~instruments~~focus on (a) real estate (subject to the exclusion of certain specified ~~classified~~projects), ~~within~~(b) media/entertainment/show ~~Level~~business, 3or (c) endorsements/advertisements/personal appearances/use of likeness/monetization of celebrity.

The following table includes a roll forward of the amounts for the quarter ended June 30, 2016 for financial instruments classified within Level 3.

Level 3 Recurring Fair Value Measurements

For the Three Months Ended ~~March~~June 3130, 2016

	Common Stock			Real Estate Company Investments		2014 Call Options		Series B Warrants			Third-Party Call Options Liability			Total
Fair value, net, January 1, 2016	$	9,896,605		$	277,500	$	1,135,863	$	1,851,750		$	(619,122	)	$	12,542,596
Fair value, net, April 1, 2016	$	8,598,030		$	277,500	$	1,135,863	$	1,268,937		$	(608,731	)	$	10,671,599
Unrealized gains (losses) included in earnings		—1,184			—		—		(~~582~~428,~~813~~890	)		1058,~~391~~187			(~~572~~369,~~422~~519	)
Purchases		—			—		—		—			—			—
Sales		(1450,~~298,575~~000	)		—		—		—			—			(1450,~~298,575~~000	)
Settlements/exercises		—			—		—		—			—			—
Transfers in and/or out of Level 3		—			—		—		—			—			—
Fair value, net, March 31, 2016	$	8,598,030		$	277,500	$	1,135,863	$	1,268,937		$	(608,731	)	$	10,671,599
Fair value, net, June 30, 2016	$	8,149,214		$	277,500	$	1,135,863	$	840,047		$	(550,544	)	$	9,852,080
Unrealized gains (losses) still held	$	7,~~593~~144,~~552~~914		$	—	$	1,135,413	$	1840,~~268,937~~047		$	(~~608~~550,~~731~~544	)	$	98,~~389~~569,~~171~~830

Level 3 Recurring Fair Value Measurements

For the Six Months Ended June 30, 2016

	Common Stock			Real Estate Company Investments		2014 Call Options		Series B Warrants			Third-Party Call Options Liability			Total
Fair value, net, January 1, 2016	$	9,896,605		$	277,500	$	1,135,863	$	1,851,750		$	(619,122	)	$	12,542,596
Unrealized gains (losses) included in earnings		4,609			—		—		(1,011,703	)		68,578			(938,516	)
Purchases		—			—		—		—			—			—
Sales		(1,752,000	)		—		—		—			—			(1,752,000	)
Settlements/exercises		—			—		—		—			—			—
Transfers in and/or out of Level 3		—			—		—		—			—			—
Fair value, net, June 30, 2016	$	8,149,214		$	277,500	$	1,135,863	$	840,047		$	(550,544	)	$	9,852,080

Unrealized gains (losses) still held	$	7,144,914		$	—	$	1,135,413	$	840,047		$	(550,544	)	$	8,569,830

Quantitative information about the valuation techniques and unobservable inputs is required to be disclosed for certain recurring and nonrecurring fair value measurements.

-2318-

(table of contents)

CAPSTONE FINANCIAL GROUP, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

NOTE 3 – FAIR VALUE MEASUREMENTS (CONTINUED)

The following tables present quantitative ~~information~~ information about the valuation techniques and unobservable inputs applied to Level 3 fair value measurements for financial instruments ~~measured~~ measured at fair value on a recurring and nonrecurring basis at ~~March~~June 3130, 2016 and December 31, 2015.

		Quantitative Information about Level 3
		Fair Value Measurements at March 31, 2016
		Fair Value Measurements at June 30, 2016
		Fair	Valuation	Unobservable	Range
		Value	Technique	Inputs
Assets
Common Stock	$	8,~~598~~149,~~030~~214	Discounted cash flow Guideline company transactions method Guideline publicly-traded company method	Growth rate Risk premium factors Revenue multiple EBITDA multiple	13.00%-15.20% (2.50%)-7.00% 1.10-2.10 9.30-13.80
2014 Call Options		1,135,863	Discounted cash flow Guideline company transactions method Guideline publicly-traded company method	Growth rate Risk premium factors Revenue multiple EBITDA multiple	13.00%-15.20% (2.50%)-7.00% 1.10-2.10 9.30-13.80
Series B Warrants		1840,~~268,937~~047	Option pricing model	Duration Risk-free interest rate Volatility	0.3309-0.6742 years 0.5220%-0.6233% 50%
Investment in Real Estate Companies		277,500	Recent transaction
Total assets held at fair value	$	1110,~~280~~402,~~330~~624
Liabilities
Call option liability	$	~~608~~550,~~731~~544	Option pricing model	Duration Risk-free interest rate Volatility	21.073-21.291 years 0.7354%-0.7557% 50%
Total liabilities held at fair value	$	~~608~~550,~~731~~544

-2419-

(table of contents)

CAPSTONE FINANCIAL GROUP, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

NOTE 3 – FAIR VALUE MEASUREMENTS (CONTINUED)

		Quantitative Information about Level 3
		Fair Value Measurements at December 31, 2015
		Fair	Valuation	Unobservable	Range
		Value	Technique	Inputs
Assets
Common Stock	$	9,896,605	Discounted cash flow Guideline company transactions method Guideline publicly-traded company method	Growth rate Risk premium factors Revenue multiple EBITDA multiple	13.00%-15.20% (2.50%)-7.00% 1.10-2.10 9.30-13.80
2014 Call Options		1,135,863	Discounted cash flow Guideline company transactions method Guideline publicly-traded company method	Growth rate Risk premium factors Revenue multiple EBITDA multiple	13.00%-15.20% (2.50%)-7.00% 1.10-2.10 9.30-13.80
Series B Warrants		1,851,750	Option pricing model	Duration Risk-free interest rate Volatility	0.25-0.92 years 0.16%-0.62% 50%
Investment in Real Estate Companies		277,500	Recent transaction
Total assets held at fair value	$	13,161,718

Liabilities
Call option liability	$	619,122	Option pricing model	Duration Risk-free interest rate Volatility	2.23-2.40 years 1.12%-1.16% 50%

Total liabilities held at fair value	$	619,122

In the ~~first~~six months ~~quarter~~ended June 30, 2016, the Company sold an aggregate of 2,305,265 shares of Twinlab common stock to various unrelated third party accredited investors, in private transactions, for $0.76 per share. In the three months ended June 30, 2016, the Company sold an aggregate of 1592,~~713,159~~106 shares of Twinlab common stock to various unrelated third party accredited investors, in in private transactions, for $0.76 per share. In addition, 4,000,000 of the Company’s warrants to purchase Twinlab common stock (for $0.76 per share) expired on March 31, 2016 in accordance with their terms.

-2520-

(table of contents)

CAPSTONE FINANCIAL GROUP, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

NOTE 4 – RELATED PARTY TRANSACTIONS

Salary Advance to Related Party

In the first quarter of 2016 the Company paid salary amounts to two of its officers covering the second, third, and fourth quarters of 2016. As a result, the Company recorded a salary advance - related party of $~~300~~200,000 at ~~March~~June 3130, 2016 in connection with such payments.

Short-Term Advances from Related Party

After October 28, 2014 the Company’s controlling stockholder Darin Pastor made advances and direct-payments to assist the Company in covering expenses. In addition, the amounts of these advances and direct-payments are reimbursable to him upon his demand at any time. At ~~March~~June 3130, 2016 and December 31, 2015, the unrepaid balance of such advances and direct-payments was $29165,~~700~~257 and $49,600, respectively.

Notes Payable to Related Party

On October 28, 2014, the Company entered into a transaction in which the Company acquired from Darin Pastor certain assets which had been assets of Affluent and assumed certain liabilities which had been liabilities of Affluent, including liabilities under demand notes in favor of Darin Pastor. The Company repaid these notes in their entirety on March 11, 2016. On December 31, 2015, the outstanding principal obligation on such assumed notes was $68,416. The interest rate on the demand notes was 2% per annum.

~~-26-~~NOTE 5 – INCOME TAXES

~~(table~~The Company accounts for income taxes under the asset and liability method, which requires the recognition of ~~contents)~~deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Income tax benefit for the three months ended June 30, 2016 was $725,412, which reflected an effective tax rate of 39.73%, which was greater than the federal statutory rate due to the state income tax expense. Income tax benefit for the six months ended June 30, 2016 was $1,225,760, which reflected an effective tax rate of 39.73%, which was greater than the federal statutory rate due to the state income tax expense.

The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant tax authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. The Company believes that, as of June 30, 2016, it does not have any uncertain tax positions.

The disclosures regarding the Company's unrecognized tax benefits at December 31, 2015 included in the Company's 2015 Annual Report on Form 10-K continue to be relevant for the period ended June 30, 2016 as to the Company’s unrecognized tax benefits at June 30, 2016.

-21-

CAPSTONE FINANCIAL GROUP, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

NOTE 5 6 – ~~INCOME~~SUBSEQUENT ~~TAXES~~EVENTS

The Company ~~accounts~~has ~~for~~evaluated ~~income~~subsequent ~~taxes~~events ~~under~~through the ~~asset~~date ~~and liability method, which requires~~ the ~~recognition~~financial ofstatements ~~deferred~~were ~~tax~~available ~~assets~~to ~~and~~be ~~liabilities for the expected future tax consequences of events that have been included in the financial statements~~issued. ~~Under~~Except ~~this~~as ~~method~~noted below, ~~deferred tax~~there ~~assets and liabilities~~ are ~~determined~~no onevents ~~the basis of the differences between the financial statement and tax bases of~~which ~~assets~~require ~~and~~adjustments ~~liabilities~~to, ~~using~~or ~~enacted~~disclosure ~~tax rates~~ in, ~~effect for~~ the ~~year~~financial instatements ~~which the differences are expected to reverse. Income tax benefit~~ for the ~~three~~periods ~~months~~ ended ~~March~~June 3130, 2016 ~~was $500,348, which reflected an effective tax rate of 39~~.~~43%, which was greater than the federal statutory rate due to the state income tax expense.~~

~~The~~In ~~impact of an uncertain income tax position~~July on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant tax authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. The disclosures regarding the Company's unrecognized tax benefits at December 312016, ~~2015 included in~~ the Company's ~~2015~~sold ~~Annual Report on Form 10-K continue to be relevant for the period ended March 31~~131,579 ~~2016~~Twinlab asshares to ~~the~~unrelated ~~Company’s~~accredited ~~unrecognized~~third ~~tax~~parties ~~benefits~~for ~~at March 31~~$100, ~~2016~~000.

~~NOTE~~In 6July ~~–SUBSEQUENT~~2016, the ~~EVENTS~~Company issued 964,706 Company shares to six accredited third parties for $820,000; certain of such investors had advanced $600,000 to the Company in the second quarter of 2016 in anticipation of the purchase of 789,473 of such shares.

~~The~~On ~~Company~~July ~~has~~31, ~~evaluated~~2016, ~~subsequent~~6,000,000 ~~events through~~of the ~~date~~Company’s warrants ~~the~~to ~~financial~~purchase ~~statements~~Twinlab ~~were~~common ~~available~~stock tounder bethe ~~issued.~~Series ~~Except~~B ~~as noted below~~Warrant, ~~there~~at ~~are~~a no$0.76 ~~events~~per ~~which~~share ~~require adjustments~~exercise toprice, orexpired ~~disclosure~~ in, ~~the~~accordance with ~~financial~~their ~~statements~~terms ~~for~~without ~~the periods ended March 31, 2016~~exercise.

InOn ~~April~~August 24, 2016, the Company entered ~~sold~~into ~~394~~a binding agreement with a major live animal wholesaler located in Oman to sell that company a total of 10,~~737~~389,250 ~~Twinlab~~hundredweight ~~shares~~of cattle and 3,142,600 hundredweight of sheep at fixed prices. (A “hundredweight” refers to ~~unrelated~~100 ~~third~~pounds ~~parties~~of ~~for~~livestock.) ~~$300~~The Company would deliver the livestock in 10 equal successive monthly installments with the first delivery to occur on September 15,~~000~~ 2016. The Company’s buyer would make corresponding monthly purchase-price payments.

The Company has matching binding contracts with well-~~27-~~established suppliers of livestock from Africa, under which by exercise of the Company’s contractual options the Company can require these suppliers to sell to the Company these same amounts of cattle and sheep, also at fixed prices.

~~(table of contents)~~-22-

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements and involves risks and uncertainties that could materially affect expected results of operations, liquidity, cash flows, and business prospects. Forward-looking statements may appear throughout this report, including without limitation, the following sections: Part I Item 2 “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements generally can be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties, which could cause our actual results to differ materially from those reflected in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on May 2, 2016, and in particular, the risks discussed under the caption “Risk Factors” in Part I Item 1A thereof, and those discussed in other documents we file with the SEC. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

Overview and Outlook

~~Our~~We ~~business~~are ~~focus~~a isdiversified tocompany ~~use~~whose ~~our own capital~~primary tobusiness ~~acquire~~focuses ~~the~~going ~~outstanding~~forward ~~equity~~include ~~securities~~(a) ~~of other companies. We do not produce goods or services ourselves. Rather, our primary purpose is~~ to ~~own~~invest ~~and~~in ~~trade~~stock ~~shares~~ of other companies., We(b) ~~seek~~ to ~~discover~~identify, ~~unlock~~pursue and ~~grow~~capitalize ~~value~~on opportunities in ~~privately-held or illiquid companies, including through~~ the ~~exercise~~minerals ofand ~~friendly~~agricultural ~~influence~~commodities atindustries ~~a company in support of operational improvements~~ and ~~strategic initiatives.~~(c) Inoverseas ~~some~~commercial ~~cases, we might be one of the largest shareholders of the other company~~lending.

WeUntil ~~seek~~the tosecond ~~work~~quarter ~~closely~~of ~~and~~2016, ~~constructively~~we ~~with~~considered ~~the~~our ~~management~~primary ~~and~~business ~~boards~~focus ofto ~~the~~be ~~other~~investing ~~companies.~~our ~~While~~own wecapital doto ~~not~~acquire ~~manage~~ the ~~day-to-day~~outstanding ~~operations~~equity securities of ~~these~~other companies. We sought, we and seek, to ~~maintain~~discover, aunlock ~~thorough understanding of how they operate~~ and ~~evaluate~~grow ~~their~~value ~~performance~~in ~~and~~privately-held ~~prospects~~or onilliquid ~~an ongoing basis~~companies.

We sought, and seek, to work closely and constructively with the management and boards of the other companies. While we do not manage the day-to-day operations of these companies, we sought, and seek, to maintain a thorough understanding of how they operate and evaluate their performance and prospects on an ongoing basis.

We may also seek to actively trade in our strategic investment positions and/or enter into private securities transactions with regard to those positions, to capitalize on price fluctuations and realize profits or minimize losses.

We were initially formed to design and sell mobile apps for smart phones and other mobile platforms such as tablets. We never launched an active business based on this focus.

During the third quarter of 2013, we refocused ourselves as a financial services company.

-28-

(table of contents)

On January 15, 2014, in support of our financial services business focus, we effected a reverse triangular merger whereby Capstone Affluent Strategies, Inc. (“Affluent”), a California corporation, became our wholly owned subsidiary. Affluent, a financial services company, had been wholly owned by Darin Pastor.

In March 2014, we refocused ourselves again, to our current business model. We believe our current business model is likely to result in lower expenses levels than would have been associated with our financial services company business model. -23-

In March 2014, we refocused ourselves again, to the business model which was our primary focus until the second quarter of 2016.

On May 14, 2014, we effectively unwound the Affluent merger transaction, due to Affluent’s inability to produce audited financial statements as required and the change in our business focus. In October 2014, we acquired from Darin Pastor certain Affluent assets and assumed certain Affluent liabilities. (Affluent had been dissolved earlier in 2014.)

Currently our primary strategic investment position is in securities of Twinlab Consolidated Holdings, Inc. (“Twinlab”). In August 2014, we purchased 10,987,500 shares of common stock of Twinlab in private transactions from 25 shareholders, for nominal consideration. Additionally, in August 2014, we purchased options to acquire 8,743,000 currently-outstanding shares of Twinlab’s common stock (collectively, the “2014 Call Options”) from 14 shareholders in a private transaction, for nominal consideration. The 2014 Call Options exercise price was $0.0001 per share and the 2014 Call Options expiration date was August 2015. (In February 2015, we exercised the Call Options. Optionors honored the exercise as to 7,244,500 Twinlab shares. Other optionors have not yet honored the exercise, as to at least 1,498,500 Twinlab shares. We intend, if necessary, to file suit to enforce the exercises as to those shares.)

On September 30, 2014, Twinlab issued to us a Series A Warrant to purchase up to 52,631,579 shares of Twinlab common stock at an exercise price of $0.76 per share (the “Series A Warrant”), and a Series B Warrant to purchase up to 22,368,421 shares of Twinlab common stock at an exercise price of $0.76 per share (the “Series B Warrant”). By their original terms, the Series A Warrant and the Series B Warrant were both exercisable from October 2014 through October 2017.

On September 30, 2014, Twinlab and we also entered into a Common Stock Put Agreement (as amended on December 15, 2014, the “Put Agreement”). Pursuant to the Put Agreement, if we did not exercise the Series A Warrant by February 16, 2015 and thereafter at a rate of no less than 1,461,988 shares of Twinlab common stock (the “Minimum Amount”) per month (the “Minimum Rate”) over the term of the Series A Warrant, Twinlab had the right (subject to certain conditions) to require us to exercise the Series A Warrant at the Minimum Rate for the duration of the Series A Warrant. In the event Twinlab exercised its right to require us to exercise the Series A Warrant, the purchase price per share of Twinlab common stock thereunder would have been $0.775. We did not exercise the “Minimum Amount” of shares per the Put Agreement. In April 2015 we exercised the Series A Warrant as to 657,895 Twinlab shares.

On October 28, 2014, we entered into a transaction in which we acquired from Darin Pastor certain assets which had been assets of Affluent and assumed certain liabilities which had been liabilities of Affluent, including liabilities under notes in favor of Darin Pastor. At December 31, 2015, the outstanding principal amount of such assumed notes was $68,416. We completed the full repayment of such assumed notes on March 11, 2016. In addition, as part of the October 28, 2014 transaction we forgave the $1,089,617 net receivable from Darin Pastor under the crossing lines of credit entered into between Affluent and us in 2013, and the crossing lines of credit were cancelled. As a result of the October 28, 2014 transactions, we recorded an expense item of $1,089,617 and we were deemed to have paid a dividend to Darin Pastor in the amount of $1,484,204.

-29-

(table of contents)

In November 2014, we sold 436,681 of our Twinlab shares for approximately $1,000,000.

-24-

During the three months ended March 31, 2015, we sold an aggregate of 3,976,647 units of Twinlab securities to various unrelated third party accredited investors. Each unit consisted of one share of (unrestricted) Twinlab common stock and a detachable call option (“Third-Party Call Options”) to purchase from us, for $1.00 per share, one (restricted) share of Twinlab common stock. The term of each such call option was three years from the respective unit sale date. In each case, the sale price per unit was $0.76 and the call option was valued at $0.156 per call option. (Our references to “unrestricted” shares mean free-trading shares, and our references to “restricted” shares mean shares that are not free-trading.).

In addition, in 2015 we sold 2,078,255 Twinlab shares (without any associated Third-Party Call Options) for $1,579,480.

In total, during 2015 we sold Twinlab securities for $4,601,732.

On May 28, 2015, we entered into a Compromise Agreement and Release and an Amendment No. 1 to Series B Warrant, each between Twinlab and us. Pursuant to these two agreements:

- The Put Agreement was terminated. - We surrendered the entire remaining-unexercised portion of the Series A Warrant (51,973,684 warrants). - We surrendered 4,368,421 of the warrants under the Series B Warrant. - The remaining 18,000,000 warrants under the Series B Warrant were deemed divided into four tranches, each with an associated date beyond which it would no longer be exercisable: one tranche for 2,000,000 warrant shares (no longer exercisable after November 30, 2015); one for 4,000,000 warrant shares (no longer exercisable after March 31, 2016); one for 6,000,000 warrant shares (no longer exercisable after July 31, 2016); and another for 6,000,000 warrant shares (no longer exercisable after November 30, 2016); - We granted Twinlab three contingent call options, at $0.01 per share, to acquire Twinlab shares from us to the extent that upon effective expiration of the second, third and fourth tranches we had not exercised the warrants within such tranches (the “Contingent Call Options”). The three Contingent Call Options would be for a number of Twinlab shares equal to 25% of such unexercised warrants (i.e., a maximum of 1,000,000 shares if we exercised no warrants from the second tranche, a maximum of 1,500,000 shares if we exercised no warrants from the third tranche and a maximum of 1,500,000 shares if we exercised no warrants from the fourth tranche). In addition, Twinlab cannot exercise a Contingent Call Option unless it has satisfied such option’s “Liquidity Condition,” namely that for each of the three or four months before the tranche’s effective expiration date Twinlab must have a financial position sufficient to show a 1.15x fixed charge coverage ratio for a certain trailing period, all as defined by Twinlab’s Credit and Security Agreement dated January 22, 2015. - Given that we have identified, and may in the future identify, to Twinlab on a confidential basis persons to whom we might sell our Twinlab shares, Twinlab agreed that it shall not, without our prior written consent, privately place Twinlab equity securities to any persons theretofore or thereafter first introduced to Twinlab by us (the “Noncircumvention Provision”); provided that Twinlab may, without our consent, privately place Twinlab equity securities to such a person at any time after the earlier of (a) the date the entire Series B Warrant has expired and/or been exercised, or (b) the first anniversary of such particular introduction.

- ~~We surrendered the entire remaining~~25-~~unexercised portion of the Series A Warrant (51,973,684 warrants).~~

- We surrendered 4,368,421 of the warrants under the Series B Warrant.

- The remaining 18,000,000 warrants under the Series B Warrant were deemed divided into four tranches, each with an associated date beyond which it would no longer be exercisable: one tranche for 2,000,000 warrant shares (no longer exercisable after November 30, 2015); one for 4,000,000 warrant shares (no longer exercisable after March 31, 2016); one for 6,000,000 warrant shares (no longer exercisable after July 31, 2016); and another for 6,000,000 warrant shares (no longer exercisable after November 30, 2016);

-30-

(table of contents)

	-	We granted Twinlab three contingent call options, at $0.01 per share, to acquire Twinlab shares from us to the extent that upon effective expiration of the second, third and fourth tranches we had not exercised the warrants within such tranches (the “Contingent Call Options”). The three Contingent Call Options would be for a number of Twinlab shares equal to 25% of such unexercised warrants (i.e., a maximum of 1,000,000 shares if we exercised no warrants from the second tranche, a maximum of 1,500,000 shares if we exercised no warrants from the third tranche and a maximum of 1,500,000 shares if we exercised no warrants from the fourth tranche). In addition, Twinlab cannot exercise a Contingent Call Option unless it has satisfied such option’s “Liquidity Condition,” namely that for each of the three or four months before the tranche’s effective expiration date Twinlab must have a financial position sufficient to show a 1.15x fixed charge coverage ratio for a certain trailing period, all as defined by Twinlab’s Credit and Security Agreement dated January 22, 2015.
	-	Given that we have identified, and may in the future identify, to Twinlab on a confidential basis persons to whom we might sell our Twinlab shares, Twinlab agreed that it shall not, without our prior written consent, privately place Twinlab equity securities to any persons theretofore or thereafter first introduced to Twinlab by us (the “Noncircumvention Provision”); provided that Twinlab may, without our consent, privately place Twinlab equity securities to such a person at any time after the earlier of (a) the date the entire Series B Warrant has expired and/or been exercised, or (b) the first anniversary of such particular introduction.

As a result of these two agreements, our investment position in Twinlab as of immediately after the two agreements was as follows:

- We had no further potential cash obligation to Twinlab under the Put Agreement; an imminent cash obligation to Twinlab of approximately $40.8 million was thereby avoided.

	-	We had no further potential cash obligation to Twinlab under the Put Agreement; an imminent cash obligation to Twinlab of approximately $40.8 million was thereby avoided.
	-	We retained all of our 14,476,567 outstanding Twinlab shares (13,818,672 unrestricted, free-trading Twinlab shares and 657,895 restricted Twinlab shares).
		-		Later in 2015 (i.e., after May 28, 2015) we sold an additional 1,749,307 unrestricted, free-trading Twinlab shares to accredited investors.
		-		In the first quarter of 2016 we sold an additional 1,713,159 unrestricted, free-trading Twinlab shares to accredited investors.
		-		We obtained an additional 526,316 restricted Twinlab shares upon a partial exercise of the Series B Warrant on July 7, 2015.
		-		We obtained an additional 131,579 restricted Twinlab shares upon a partial exercise of the Series B Warrant on July 23, 2015.
	-	Our obligations to our accredited-investor counterparties under the 3,976,647 Third-Party Call options continued unchanged.
	-	We retained 18,000,000 warrants under the Series B Warrant, at an unchanged $0.76 per share exercise price, with effective expiration dates ranging from November 30, 2015 to November 30, 2016.
		-		We exercised 526,316 of such warrants on July 7, 2015.
		-		We exercised 131,579 of such warrants on July 23, 2015.
		-		1,342,105 of such warrants expired on November 30, 2015.
		-		4,000,000 of such warrants expired on March 31, 2016.
-		The Registration Rights Agreement remains in full force and effect to enable the Securities Act registration of all Twinlab shares issued upon exercise of the Series B Warrant.
-		Under the Contingent Call Options, we undertook a contingent obligation to deliver to Twinlab (at $0.01 per share) up to 4,000,000 Twinlab shares, but the obligation would be reduced or entirely eliminated to the extent we exercise the last three deemed tranches of the Series B Warrant and/or to the extent that Twinlab fails to meet a required fixed charge coverage ratio for certain months. The redelivered Twinlab shares would not have to be free-trading Twinlab shares.
		-	As noted below, the Contingent Call Options were eliminated on October 1, 2015.

-	We retained all of our 14,476,567 outstanding Twinlab shares (13,818,672 unrestricted, free-trading Twinlab shares and 657,895 restricted Twinlab shares).
	-	Later in 2015 (i.e., after May 28, 2015) we sold an additional 1,749,307 unrestricted, free-trading Twinlab shares to accredited investors.
	-	In the first quarter of 2016 we sold an additional 1,713,159 unrestricted, free-trading Twinlab shares to accredited investors.
	-	We obtained an additional 526,316 restricted Twinlab shares upon a partial exercise of the Series B Warrant on July 7, 2015.
	-	We obtained an additional 131,579 restricted Twinlab shares upon a partial exercise of the Series B Warrant on July 23, 2015.

-31-

(table of contents)

-	Our obligations to our accredited-investor counterparties under the 3,976,647 Third-Party Call options continued unchanged.
-	We retained 18,000,000 warrants under the Series B Warrant, at an unchanged $0.76 per share exercise price, with effective expiration dates ranging from November 30, 2015 to November 30, 2016 (and with at least 14 months of remaining term for 12,000,000 of the warrants).
	-	We exercised 526,316 of such warrants on July 7, 2015.
	-	We exercised 131,579 of such warrants on July 23, 2015.
	-	1,342,105 of such warrants expired on November 30, 2015.
	-	4,000,000 of such warrants expired on March 31, 2016.

- The Registration Rights Agreement remains in full force and effect to enable the Securities Act registration of all Twinlab shares issued upon exercise of the Series B Warrant.

- Under the Contingent Call Options, we undertook a contingent obligation to deliver to Twinlab (at $0.01 per share) up to 4,000,000 Twinlab shares, but the obligation would be reduced or entirely eliminated to the extent we exercise the last three deemed tranches of the Series B Warrant and/or to the extent that Twinlab fails to meet a required fixed charge coverage ratio for certain months. The redelivered Twinlab shares would not have to be free-trading Twinlab shares. - As noted below, the Contingent Call Options were eliminated on October 1, 2015.

On July 5, 2015, Twinlab and we entered into an Agreement for Limited Waiver of Noncircumvention Provision (the “Limited Waiver Agreement”), pursuant to which we agreed to waive the Noncircumvention Provision as to a particular potential investor (B. Thomas Golisano) whom we had introduced to Twinlab in June 2015 and to whom the Noncircumvention Provision would otherwise apply, in exchange for substantial compensation in cash and Twinlab warrants calculated on the basis of the size and pricing of such investor’s purchase(s) of Twinlab securities.

-26-

On October 1, 2015, Twinlab and we entered into an Amendment No. 1 to Agreement for Limited Waiver of Non-Circumvention Provision and to Compromise Agreement and Release, pursuant to which the Limited Waiver Agreement was amended to remove our right to any compensation for the waiver of the Noncircumvention Provision as to B. Thomas Golisano and his affiliates, and the Compromise Agreement and Release was amended to eliminate the three Contingent Call Options.

During the ~~three~~six months ended ~~March~~June 3130, ~~2016~~ 2016 we sold 12,~~713~~305,~~159~~265 Twinlab shares (without any associated Third-Party Call Options) for $1,~~302~~752,000.

~~-32-~~As of June 30, 2016, our position in Twinlab securities was as follows, and we had no contingent liabilities to Twinlab:

- We held 10,750,942 outstanding Twinlab shares (~~table~~9,764,100 unrestricted, free-trading Twinlab shares and 986,842 restricted Twinlab shares). - We held 12,000,000 warrants under the Series B Warrant, at a $0.76 per share exercise price, with effective expiration dates at July 31, 2016 (as to 6,000,000 of ~~contents~~such warrants) and November 30, 2016 (as to the other 6,000,000 of such warrants). - The Registration Rights Agreement remains in full force and effect to enable the Securities Act registration of all Twinlab shares issued upon prior or future exercises of our Warrants. - We have a claim against third-party optionors for delivery to us of 1,498,500 Twinlab shares against the Call Options which they granted to us and which we have exercised. - We are contingently obligated to deliver Twinlab shares to our accredited-investor counterparties under the 3,976,647 Third-Party Call options if and when the detachable call options are exercised. - We have no actual or potential Put liability or Contingent Call Option liability.

AsAt June ~~of March 31~~30, 2016, ~~(and~~the ~~also~~fair ~~giving~~value ~~effect to~~of the ~~March~~liability ~~31,~~under ~~2016~~the ~~expiration of 4~~3,~~000~~976,~~000~~647 ofThird-Party ~~the~~Call ~~Series~~Options Bwas ~~Warrants),~~recorded on our ~~position~~balance ~~in Twinlab securities was as follows, and~~sheet weat ~~had no contingent liabilities to Twinlab:~~$550,544.

-The determination Weof ~~held~~the 11fair value of our Twinlab stock and derivative securities as of June 30,~~343~~ 2016 is highly significant to our balance sheet and our income statement. In determining the fair value,~~048~~ ~~outstanding~~our ~~Twinlab~~Board ~~shares~~of ~~(10~~Directors relied upon a valuation report dated March 2,~~356~~ 2016 by an independent third party valuation firm. This valuation report,~~206~~ ~~unrestricted~~which we commissioned, ~~free-trading~~values Twinlab common ~~shares~~stock ~~and~~at ~~986~~$0.758 per share as of December 31,~~842~~ ~~restricted~~2015. Twinlab stock is essentially illiquid; accordingly, valuations such as FFG’s are opinions, and other observers might have valued Twinlab stock differently if they chose to emphasize other factors than FFG did. For example, Twinlab issued significant numbers of shares in the second half of 2015 at prices well below $0.758 per share. If we used in our financial statements a valuation of Twinlab stock (as of June 30, 2016) which was well below $0.758 per share, with corresponding valuations for our Twinlab derivative securities, our net assets as of June 30, 2016 would have been significantly reduced and we would have had a significantly larger net loss in the second quarter and first six months of 2016.

- We held 12,000,000 warrants under the Series B Warrant, at a $0.76 per share exercise price, with effective expiration dates at July 31, 2016 (as to 6,000,000 of such warrants) and November 30, 2016 (as to the other 6,000,000 of such warrants).27-

- The Registration Rights Agreement remains in full force and effect to enable the Securities Act registration of all Twinlab shares issued upon prior or future exercises of our Warrants.

- We have a claim against third-party optionors for delivery to us of 1,498,500 Twinlab shares against the Call Options which they granted to us and which we have exercised.

- We are contingently obligated to our accredited-investor counterparties under the 3,976,647 Third-Party Call options.

- We have no actual or potential Put liability or Contingent Call Option liability.

At March 31, 2016, the fair value of the liability under the 3,976,647 Third-Party Call Options was recorded on our balance sheet at $608,731.

The determination of the fair value of our Twinlab stock and derivative securities as of March 31, 2016 is highly significant to our balance sheet and our income statement. In determining the fair value, our Board of Directors relied upon a valuation report dated March 2, 2016 by an independent third party valuation firm. This valuation report, which we commissioned, values Twinlab common stock at $0.758 per share as of December 31, 2015. Twinlab stock is essentially illiquid; accordingly, valuations such as FFG’s are opinions, and other observers might have valued Twinlab stock differently if they chose to emphasize other factors than FFG did. For example, Twinlab issued significant numbers of shares in the second half of 2015 at prices well below $0.758 per share. If we used in our financial statements a valuation of Twinlab stock (as of March 31, 2016) which was well below $0.758 per share, with corresponding valuations for our Twinlab derivative securities, our net assets as of March 31, 2016 would have been significantly reduced and we would have had a significantly larger net loss in the first quarter of 2016.

In July 2015, in exchange for $277,500, we acquired a 20% interest in privately-held Western New York real estate companies LC Strategic Realty, LLC and LC Strategic Holdings, LLC, as well as in all other business conducted by the firms’ majority holders to the extent such other business has a primary focus on (a) real estate (subject to the exclusion of certain specified projects), (b) media/entertainment/show business, or (c) endorsements/advertisements/personal appearances/use of likeness/ monetization of celebrity.

-33-

(table of contents)

On June 17 and 18, 2015, we filed a Form 4 and an amended Schedule 13D statement to report a June 10, 2015 sale by us of 13,157,895 shares of Twinlab common stock to a third party. The third party did not timely honor its payment obligation under the sale contract and we have treated the transaction as a non-event for financial reporting purposes. On December 18, 2015, we terminated the sale contract.

We ~~currently~~continue ~~are~~to ~~considering~~investigate ~~electing~~possible acquisitions toof ~~become a~~positions ~~Business~~in ~~Development~~new ~~Company~~businesses, securities and~~/or~~ ~~filing~~assets, ~~(or~~and ~~causing~~evaluate anthe ~~affiliated~~retention ~~company~~and todisposition ~~file)~~of anour ~~application~~existing holdings. Changes ~~with~~in the ~~United~~mix ~~States~~of ~~Small Business~~our ~~Administration~~businesses toand ~~become~~investments ashould ~~Small~~be ~~Business Investment Company~~expected. We ~~can~~have ~~give~~in nothe ~~assurance~~past ~~that~~taken ~~such~~preliminary steps antoward ~~application~~acquisitions ~~will~~and ~~be filed~~investments orin ~~that~~various companies, ifwhich ~~filed~~transactions were never completed, itand ~~will~~we behave ~~granted~~made an unsuccessful investment (in Blackcraft Cult, Inc. common stock) which we continue to hold but have written down to a zero valuation.

In addition, we are working toward ~~substantial~~ substantial opportunities in the precious minerals, mining and agricultural commodities industries and energy-related development projects, ~~and~~as ~~substantial~~well ~~international~~as ~~minerals~~other ~~trading~~substantial ~~projects~~international opportunities. We can give no assurance that such ~~projects~~ projects will come to fruition or, if any one or more of them do come to fruition, that they will be successful.

WeResults ~~continuously investigate possible acquisitions~~ of ~~positions~~Operations infor ~~new businesses, securities and assets, and evaluate~~ the ~~retention and disposition of our existing holdings. Changes~~Quarterly inPeriods ~~the~~Ended ~~mix~~June ~~of our businesses and investments should be expected. We have in the past taken preliminary steps toward acquisitions and investments in various companies~~30, ~~which~~2016 ~~transactions were never completed,~~ and ~~we have made an unsuccessful investment (in Blackcraft Cult, Inc. common stock) which we continue to hold but have written down to a zero valuation.~~2015

~~Results~~Revenues. Total revenues of(excluding ~~Operations~~gain and loss on investment securities) for the ~~Quarterly Periods~~quarters ~~Ended~~ended ~~March~~June 3130, 2016 and 2015 were $3,600 (sublease income) and $57,015. The 2015 period included services income of $50,001. Due to our current business focus, we do not expect to regularly generate material amounts of services income.

~~Revenues. Total~~Realized ~~revenues (excluding gain~~ and ~~loss~~Unrealized onGain ~~investment securities~~(Loss) ~~for~~on Financial ~~the~~Instruments. ~~quarters~~We ~~ended~~recorded ~~March~~a ~~31, 2016 and 2015 were~~ $12449,~~000~~823 ~~and~~realized ~~$57,447.~~again ~~There was~~on ~~$12,000~~financial ofinstruments ~~sublease~~for ~~income~~the ~~from~~quarter ~~two~~ended ~~sublessees~~June 30, ~~in the~~ 2016, ~~period.~~as ~~The~~a ~~2015~~result ~~period included services income~~ of ~~$50,001. Due to~~ our ~~current~~sales ~~business~~of ~~focus,~~Twinlab weshares ~~do not expect~~ to ~~regularly~~third ~~generate~~parties ~~material~~during ~~amounts~~the ofquarter ~~services~~for ~~income~~$450,000.

~~Realized and Unrealized Gain (Loss) on Financial Instruments.~~ We also recorded a $1(819,~~302,000~~342) ~~realized~~change in unrealized gain on financial instruments for the quarter ended ~~March~~June 3130, 2016, primarily as a result of the transformation of unrealized gain into realized gain upon our sales of Twinlab shares to third parties during the quarter, ~~for~~as ~~$1,302,000~~well as reductions in the valuation of our Twinlab warrants as the remaining time until their expiration dates decreases.

WeThe ~~also~~overall ~~recorded~~net ~~a $1,870,997 change in unrealized~~ loss on financial instruments for the quarter ~~ended~~was ~~March 31~~$369, ~~2016, primarily as a result of the March 31, 2016 expiration of 4,000,000 of our Twinlab common stock warrants~~519.

~~The overall net loss on financial instruments for the quarter was $568,997.~~ -28-

~~-34-~~If our assessments/estimates of the fair value of our holdings of Twinlab securities change from quarter to quarter, there will be significant changes in our unrealized gain or loss on such holdings, which in turn would result in significant gain or loss on our statement of operations for the quarter in question. At December 31, 2014, March 31, 2015 and June 30, 2015, our determination was that the fair value of Twinlab common stock was $0.76 per Twinlab share. However, at September 30, 2015, our determination was that the fair value of Twinlab common stock was $0.65 per Twinlab share and at December 31, 2015, March 31, 2016 and June 30, 2016, our determination was that the fair value of Twinlab common stock was $0.758 per Twinlab share. We ourselves continued to sell Twinlab shares for $0.76 in the second quarter of 2016.

(table of contents)

If our assessments/estimates of the fair value of our holdings of Twinlab securities change from quarter to quarter, there will be significant changes in our unrealized gain on such holdings, which in turn would result in significant gain or loss on our statement of operations for the quarter in question. At December 31, 2014, March 31, 2015 and June 30, 2015, our determination was that the fair value of Twinlab common stock was $0.76 per Twinlab share. However, at September 30, 2015, our determination was that the fair value of Twinlab common stock was $0.65 per Twinlab share and at December 31, 2015 and March 31, 2016, our determination was that the fair value of Twinlab common stock was $0.758 per Twinlab share. We ourselves continued to sell Twinlab shares for $0.76 in the first quarter of 2016.

We first acquired ownership of any Twinlab securities in the third quarter of 2014.

Personnel Expense. Personnel expense for the quarters ended ~~March~~June 3130, 2016 and 2015 was $~~170~~180,~~908~~952 and $4348,~~387~~158, respectively; the increase in 2016 was primarily due to salary payments of $360,000 to Darin Pastor and $40,000 to Tracy Pastor in the first quarter of 2016. These amounts are attributable to the entire 2016 year, so $100,000 of such amounts were recognized as personnel expense for the ~~first~~second quarter of 2016 and $~~300~~200,000 of such amounts were recorded at ~~March~~June 3130, 2016 as a salary advance - related party asset. Before 2016, we had held the salaries of our most senior officers at very low levels.

Professional Fees. Professional fees for the quarters ended ~~March~~June 3130, 2016 and 2015 were $92443,~~602~~683 and $~~260~~340,~~998~~596, respectively., ~~The~~each ~~high figure for the 2015 period was~~ primarily due to legal fees for preparing documents for production as required by legal process.

General and Administrative. General and administrative expenses (excluding personnel expense and professional fees) for the quarters ended ~~March~~June 3130, 2016 and 2015 ~~were~~ were $~~447~~825,~~941~~508 and $~~156~~151,~~708~~617, respectively; the increase in 2016 was primarily due to overseas business development efforts ~~and increased activities following our move to our East Amherst headquarters in May 2015~~.

Results of Operations for the Six Months Periods Ended June 30, 2016 and 2015

Revenues. Total revenues (excluding gain and loss on investment securities) for the six months periods ended June 30, 2016 and 2015 were $15,600 and $114,462. There was $15,600 of sublease income from two sublessees in the 2016 period. The 2015 period included services income of $100,002. Due to our current business focus, we do not expect to regularly generate material amounts of services income.

Realized and Unrealized Gain (Loss) on Financial Instruments. We recorded a $1,751,309 realized gain on financial instruments for the six months period ended June 30, 2016, as a result of our sales of Twinlab shares to third parties during the six months period for $1,752,000.

We also recorded a $(2,689,825) change in unrealized gain on financial instruments for the six months period ended June 30, 2016, primarily as a result of the March 31, 2016 expiration of 4,000,000 of our Twinlab common stock warrants.

The overall net loss on financial instruments for the six months period was $938,516.

-29-

If our assessments/estimates of the fair value of our holdings of Twinlab securities change from quarter to quarter, there will be significant changes in our unrealized gain or loss on such holdings, which in turn would result in significant gain or loss on our statement of operations for the quarter in question. At December 31, 2014, March 31, 2015 and June 30, 2015, our determination was that the fair value of Twinlab common stock was $0.76 per Twinlab share. However, at September 30, 2015, our determination was that the fair value of Twinlab common stock was $0.65 per Twinlab share and at December 31, 2015, March 31, 2016 and June 30, 2016, our determination was that the fair value of Twinlab common stock was $0.758 per Twinlab share. We ourselves continued to sell Twinlab shares for $0.76 in the first and second quarters of 2016.

We first acquired ownership of any Twinlab securities in the third quarter of 2014.

Personnel Expense. Personnel expense for the six months periods ended June 30, 2016 and 2015 was $351,860 and $91,545, respectively; the increase in 2016 was primarily due to salary payments of $360,000 to Darin Pastor and $40,000 to Tracy Pastor in the first quarter of 2016. These amounts are attributable to the entire 2016 year, so $100,000 of such amounts were recognized as personnel expense for each of the first and second quarters of 2016 and $200,000 of such amounts were recorded at June 30, 2016 as a salary advance - related party asset. Before 2016, we had held the salaries of our most senior officers at very low levels.

Professional Fees. Professional fees for the six months periods ended June 30, 2016 and 2015 were $536,286 and $601,594, respectively, each primarily due to legal fees for preparing documents for production as required by legal process.

General and Administrative. General and administrative expenses (excluding personnel expense and professional fees) for the six months periods ended June 30, 2016 and 2015 were $1,273,448 and $308,325, respectively; the increase in 2016 was primarily due to overseas business development efforts.

Liquidity and Capital Resources

As of ~~March~~June 3130, 2016, we had $~~323~~102,~~947~~ 282 in cash and cash equivalents, Twinlab and other securities owned which we recorded at ana $1110,~~280~~402,~~330~~624 fair value, and $63,930 of deposits. There is no active liquid public market for our Twinlab or other securities.

We anticipate obtaining additional financing to fund operations through common stock offerings, sales of Twinlab stock and sales of future-acquired strategic investment securities, and bank loans, to the extent available. There can be no assurance we will be successful in raising the necessary funds to execute our business plan. The realization of cash proceeds, if any, on sales of our securities positions would likely be “bunchy,” ~~unpredictable~~ unpredictable and irregular. We can make no assurances and therefore we may incur operating losses and/or negative cash flows in one or more future periods.

~~-35-~~It is possible that we might use meaningful amounts of any free cash flow we generate to make further partial exercises of the Series B Warrant, in order both to help Twinlab maintain and grow its business (thereby benefiting the value of our remaining Twinlab securities) and to avoid or reduce the risk of in effect having a “short” position in Twinlab stock (as described in the following paragraph).

~~(table of contents)~~-30-

~~Our~~The ~~current~~June ~~intention~~30, is2016 tobalance ~~use~~sheet ~~meaningful~~included ~~amounts~~a of$550,544 ~~any~~liability ~~free~~item ~~cash~~arising ~~flow~~from the Third-Party Call Options we ~~generate~~granted to ~~make~~certain ~~further~~accredited ~~partial~~investors ~~exercises~~in connection with certain of our 2015 sales of Twinlab common stock to such investors. Our actual risk under the Third-Party Call Options would be magnified if, due to sales of Twinlab common stock and/or expiration of unexercised Series B ~~Warrant~~Warrants, inwe ~~order~~do ~~both~~not tohave ~~help~~as many Twinlab ~~maintain~~shares and/or ~~grow~~available ~~its~~Series ~~business~~B ~~(thereby~~Warrants ~~benefiting~~as the ~~value~~number of ~~our~~shares ~~remaining~~we ~~Twinlab~~could ~~securities)~~be ~~and~~obliged to ~~avoid~~deliver orunder ~~reduce~~ the ~~risk~~Third-Party Call Options of(i.e., to the extent we in effect ~~having~~are “short” Twinlab shares). The expiration date of the Third-Party Call Options is a substantial number of months after the expiration of the Series B Warrants. If we wish to avoid being “short” Twinlab ~~position~~shares in ~~Twinlab~~the ~~stock~~manner ~~(as~~just described, init may be necessary for us to purchase and hold Twinlab shares through the ~~following~~expiration date ~~paragraph)~~of the Third-Party Call Options, which would tie up a large amount of otherwise available cash. If insufficient cash is available for this purpose, it may be necessary for us to run the risk of having what in effect is a short position.

The ~~March 31~~$3,355,452 ~~2016~~deferred ~~balance~~tax ~~sheet included a $608,371~~ liability item ~~arising~~on ~~from the Third-Party Call Options we granted to certain accredited investors in connection with certain of~~ our ~~2015~~June ~~sales~~30, of2016 ~~Twinlab~~balance ~~common~~sheet ~~stock~~represents ~~to such investors. Our actual risk under~~ the ~~Third-Party~~income ~~Call~~taxes ~~Options~~we would ~~be magnified~~owe if, ~~due~~we ~~to sales of Twinlab common stock and/or expiration of unexercised Series B Warrants~~sold, weduring dotax ~~not~~years ~~have~~in aswhich ~~many~~our ~~Twinlab~~taxable ~~shares~~income ~~and/or~~levels ~~available~~were ~~Series~~large Benough ~~Warrants as the number of shares we could be obliged~~ to ~~deliver~~support ~~under~~such ~~the~~current ~~Third-Party~~income ~~Call Options (i.e.~~taxes, toall the ~~extent we in effect are “short”~~ Twinlab ~~shares).~~securities ~~The~~which ~~expiration~~we ~~date~~held as of ~~the~~June ~~Third-Party~~30, ~~Call Options~~2016, isat a ~~substantial~~price ~~number~~resulting ofin ~~months~~realization ~~after~~of ~~the~~all ~~expiration~~ of the ~~Series~~unrealized Bgain ~~Warrants. If~~ we ~~wish~~recorded ~~to avoid being “short” Twinlab shares in the manner just described, it may be necessary~~ for ussuch toassets ~~purchase~~on ~~and~~our ~~hold~~balance ~~Twinlab~~sheet ~~shares~~(based ~~through~~on ~~the expiration~~our ~~date~~fair ofvalue ~~the~~assessment ~~Third-Party~~as ~~Call~~of ~~Options~~June 30, ~~which~~2016). ~~would~~No ~~tie~~such uptaxes awould ~~large~~be ~~amount~~actually ofpayable ~~otherwise~~unless ~~available~~and ~~cash.~~until Ifafter ~~insufficient~~we ~~cash~~sell isthe ~~available~~Twinlab ~~for this purpose~~securities, itand ~~may be necessary for us to run~~ the ~~risk~~amount of ~~having~~actual ~~what~~taxes inpayable ~~effect~~would isdepend aon ~~short~~the ~~position~~actual sales prices.

~~The~~From ~~$4,047,557~~time ~~deferred~~to ~~tax~~time ~~liability~~after ~~item~~October 28, on2014 our ~~March~~controlling ~~31,~~stockholder ~~2016~~Darin ~~balance~~Pastor ~~sheet~~has ~~represents~~made ~~the~~advances ~~income~~and ~~taxes~~direct-payments weto ~~would~~assist ~~owe~~us ifin wecovering ~~sold,~~expenses; ~~during~~he ~~tax~~is ~~years in which our taxable~~not ~~income~~obligated ~~levels were large enough~~ to ~~support~~make any such ~~current~~advances ~~income~~and ~~taxes,~~direct-payments ~~all~~and ~~the~~there ~~Twinlab~~can ~~securities~~be ~~which~~no weassurance ~~held~~that asany ofsuch ~~March~~advances ~~31,~~and direct-payments ~~2016,~~will atcontinue. aIn ~~price~~addition, ~~resulting~~the inamounts ~~realization~~ of ~~all~~these ofadvances ~~the~~and ~~unrealized~~direct-payments ~~gain~~are wereimbursable ~~recorded~~to ~~for~~him ~~such~~upon ~~assets~~his ondemand ~~our~~at ~~balance~~any ~~sheet (based~~time. onAt ~~our~~June ~~fair value assessment as of March 31~~30, 2016)., ~~No such taxes would be actually payable unless and until after we sell the Twinlab securities~~$165,257 ~~and the amount~~ of ~~actual~~such ~~taxes~~advances ~~payable~~and ~~would~~direct-payments ~~depend~~had onnot ~~the~~yet ~~actual~~been ~~sales prices~~reimbursed.

From time to time after October 28, 2014 our controlling stockholder Darin Pastor has made advances and direct-payments to assist us in covering expenses; he is not obligated to make any such advances and direct-payments and there can be no assurance that any such advances and direct-payments will continue. In addition, the amounts of these advances and direct-payments are reimbursable to him upon his demand at any time. At March 31, 2016, $29,700 of such advances and direct-payments had not yet been reimbursed.

The entire $68,416 remaining balance on the notes payable to Darin Pastor, which we assumed as part of our October 2014 transaction involving assets and liabilities of the former Capstone Affluent Strategies, Inc., plus $19 of accrued but unpaid interest, was repaid on March 11, 2016.

We remind readers that our prospects must be considered in light of the risks, expenses and difficulties frequently encountered by emerging companies. Also, our limited operating history makes predictions of future operating results and cash needs difficult to ascertain.

The following table provides detailed information about our net cash flow for the respective first ~~three~~six months of our 2016 and 2015 fiscal years.

-36-

	For the six month periods ended June 30,
	2016			2015
Net cash (used in) provided by operating activities	$	(681,808	)	$	2,208,951
Net cash used in investing activities		—			(2,039	)
Net cash provided by (used in) financing activities		647,241			(659,175	)
Net (decrease) increase in cash		(34,567	)		1,547,737
Cash, beginning		136,849			12,685
Cash, ending	$	102,282		$	1,560,422

~~(table of contents)~~-31-

	For the three month periods ended March 31,
	2016			2015
Net cash provided by operating activities	$	275,414		$	560,667
Net cash used in financing activities		(88,316	)		(450,000	)
Net increase in cash		187,098			110,667
Cash, beginning		136,849			12,685
Cash, ending	$	323,947		$	123,352

Operating activities

Net cash ~~provided~~used byin operating ~~activities~~ activities was $~~275~~681,~~414~~808 for the first ~~three~~six months of 2016, ~~despite~~primarily due to our $~~768~~1,~~445~~889,003 after-tax net loss for that ~~three~~six months period. Although our sales of Twinlab securities in the first ~~three~~six months of 2016 generated $1,~~302~~752,000 in cash proceeds, the $1(2,~~870~~689,~~997~~825) net change in unrealized gain on financial instruments, which was primarily due to the expiration of 4,000,000 of our Twinlab warrants, ~~and~~was a ~~the ($1,302,000) net change in realized gain on financial instruments were~~ noncash ~~items~~item. Our determination was that the fair value of Twinlab common stock was $0.758 per share as of both ~~March~~June 3130, 2016 and December 31, 2015.

For the first ~~three~~six months period of 2015, net cash provided by operating activities was $~~560~~2,~~667 for the first three months of 2016~~208,951, despite our $~~408~~2,~~702~~134,972 after-tax net loss for that ~~three~~six months period. Although our sales of Twinlab securities in the first ~~three~~six months of 2015 generated substantial cash proceeds, we did not record an overall net gain on financial instruments on such sales to the extent that the sales prices (ranging from $0.60 to $0.76 per share) were below or equal to the fair value we had determined for our Twinlab stock and at which we were carrying the Twinlab stock on our books.

Financing activities

Net cash ~~used~~provided inby financing activities in the first ~~three~~six months of 2016 was primarily attributable to ~~our~~$600,000 advanced by accredited investors against a private placement of our newly-issued common stock which closed in July 2016. Our final repayment of notes owed to ~~controlling~~our controlling stockholder Darin Pastor ~~and~~was tomore ~~partial~~than ~~prepayment~~offset ofby a net increase in Darin Pastor’s ~~prior~~ advances and direct-payments to us during the six-months period to assist us in covering expenses; he is not obligated to make any such advances and direct-payments and there can be no assurance that any such advances and direct-payments will continue. In addition, the amounts of these advances and direct-payments are reimbursable to him upon his demand at any time.

The net cash used in financing activities in in the first ~~three~~six months of 2015 was primarily attributable to repayments on notes payable to Darin Pastor.

-37-

(table of contents)

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Critical Accounting Policies and Estimates

The preparation of our financial statements in conformity with accounting principles generally accepted in the United States and the accounting and financial reporting conventions of the investment company industry requires us to make estimates and judgments that affect our reported assets, liabilities, revenues, and expenses, and the disclosure of contingent assets and liabilities. We base our estimates and judgments on historical experience and on various other assumptions, we believe to be reasonable under the circumstances. Future events, however, may differ markedly from our current expectations and assumptions.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

This item is not applicable, as we are classified as a smaller reporting company.

-32-

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

As required by Rule 13a-15 under the ~~Securities~~ Securities Exchange Act, as of ~~March~~June 3130, 2016 we carried out an evaluation of the effectiveness of the design and operation of our ~~disclosure~~ disclosure controls and procedures. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, who concluded that our disclosure controls and procedures are effective. The errors which required the restatement of financial statements and the amendments of periodic reports, as reported and summarized in our Current Report on Form 8-K filed on November 13, 2014 (as amended on November 24, 2014) and in such amendments and as further ~~stated~~ stated in the following paragraph of this item, were, in their judgment, not due to ineffectiveness of our disclosure controls and procedures.

-38-

(table of contents)

Internal Control Over Financial Reporting

Our management is responsible for preparing our annual consolidated financial statements and for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) promulgated under the Securities Exchange Act of 1934 as a process designed by, or under the supervision of, a company’s principal executive and principal financial officers and effected by a company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

· Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company; · Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and · Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements.

· Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and -33-

· Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements.

All internal control systems, no matter how well designed, have inherent limitations and can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

Our management assessed the effectiveness of our internal control over financial reporting as of June 30, 2016. In making our assessment, we used the framework and criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-~~39-~~Integrated Framework in 2014. Based on that assessment, our management has identified certain material weaknesses in our internal control over financial reporting.

~~(table~~Our management concluded that as of June ~~contents)~~30, 2016 our internal control over financial reporting was not effective, and that material weaknesses existed in the following areas as of June 30, 2016:

Our management assessed the effectiveness of our internal control over financial reporting as of March 31, 2016. In making our assessment, we used the framework and criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework in 2014. Based on that assessment, our management has identified certain material weaknesses in our internal control over financial reporting.

(1)		we do not employ full time in-house personnel with the technical knowledge to identify and address some of the reporting issues surrounding certain complex or non-routine transactions. With respect to material, complex and non-routine transactions, management has and will continue to seek guidance from third-party experts and/or consultants to gain a thorough understanding of these transactions;
(2)		we have inadequate segregation of duties consistent with the control objectives including but not limited to the disbursement process, transaction or account changes, and the performance of account reconciliations and approval;
(3)		we have ineffective controls over the period end financial disclosure and reporting process caused by reliance on third-party experts and/or consultants and insufficient accounting staff; and
(4)		we do not have a functioning audit committee of the Board of Directors and our Board of Directors, in its performance of the functions generally associated with audit committees, lacks a majority of (indeed, lacks any) independent members and lacks a majority of (indeed, lacks any) outside directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls, approvals and procedures.

Our management concluded that as of March 31, 2016 our internal control over financial reporting was not effective, and that material weaknesses existed in the following areas as of March 31, 2016:

(1) we do not employ full time in-house personnel with the technical knowledge to identify and address some of the reporting issues surrounding certain complex or non-routine transactions. With respect to material, complex and non-routine transactions, management has and will continue to seek guidance from third-party experts and/or consultants to gain a thorough understanding of these transactions;

(2) we have inadequate segregation of duties consistent with the control objectives including but not limited to the disbursement process, transaction or account changes, and the performance of account reconciliations and approval;

(3) we have ineffective controls over the period end financial disclosure and reporting process caused by reliance on third-party experts and/or consultants and insufficient accounting staff; and

(4) we do not have a functioning audit committee of the Board of Directors and our Board of Directors, in its performance of the functions generally associated with audit committees, lacks a majority of (indeed, lacks any) independent members and lacks a majority of (indeed, lacks any) outside directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls, approvals and procedures.

To attempt to remediate these material weaknesses (which have also been noted during previous quarterly assessments), we have in previous quarters increased (and plan to enhance in the future) our use of external accounting services, adopted in previous quarters (and plan to further adopt in the future) policies to improve timely reviews by management and coordination with accounting consultants, and are increasing our use of experienced corporate and securities legal counsel, and we plan to add financial department employees as our resource priorities allow. We believe these actions will continue to improve items (1), (2) and (3) noted above.

Changes in Internal Control Over Financial Reporting

No substantial changes in our internal control over financial reporting occurred during the ~~first~~second quarter of 2016 that have materially affected, or or are reasonably likely to to materially affect, ~~our~~ our internal control ~~over~~ over financial reporting.

-4034-

(table of contents)

PART II

Item 1. Legal Proceedings

We are not a party to any material legal proceedings.

Item 1A. Risk Factors

This item is not applicable, as we are classified as a smaller reporting company. To better inform the readers of this Quarterly Report on Form 10-Q, however, we refer to the Risk Factors set forth in Part I, Item 1A of our Annual Report on Form 10-K filed with the Securities and Exchange Commission on May 2, 2016, and to certain other risks identified within this Quarterly Report on Form 10-Q.

In addition, investors should take note that we carry our strategic investments at market value or, if there is no readily available market value, at fair value as determined by our board of directors in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and the accounting and financial reporting conventions of the investment company industry. Typically, there is not a liquid public market for the securities of the companies in which we intend to invest. Where a liquid public market exists we would simply use market value, but where there is no public market or where the public market is illiquid (with the result that the reported public trading is not a reliable indicator of true value), we will value these securities quarterly at fair value as determined in good faith by our Board of Directors.

Because such valuations are inherently uncertain, may fluctuate over short periods of time and may be based on estimates, our determinations of fair value may differ materially from the values that would have been used if a ready market for these securities existed. Due to this uncertainty, our determinations of the fair value of our trading positions on a given date may be materially understated or overstated compared to the value that we may ultimately realize upon the sale of those positions. Indeed, our determinations might be inaccurate even as of the determination date.

There is no guarantee that we will be able to realize the fair value as evaluated by our Board of Directors upon disposition of the asset.

Given that a large percentage of our assets and net income are based on our fair value figures for Twinlab securities, readers should be especially aware of the risk.

In addition, investors should be aware that the opportunities we are pursuing in the minerals industry tend to be exceptionally high-~~41-~~risk, and investors should also be aware that these opportunities have not yet come to fruition.

(table of contents)

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

~~We made no unregistered issuances of our securities during the quarter ended March 31, 2016~~None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

-35-

Item 5. Other Information

Not applicable.

-42-

(table of contents)

Item 6. Exhibits

(a) The following exhibits are included as part of this report:

			Incorporated by reference
Exhibit		Filed			Filing
Number	Exhibit Description	herewith	Form	Exhibit	date
2.1	Stock Purchase Agreement dated September 6, 2013 between Ryan Faught and Darin Pastor		10-K	2.1	2/18/2015
2.2	Stock Purchase Agreement dated September 6, 2013 between Ryan Faught and George L. Schneider		10-K	2.2	2/18/2015
2.3	Agreement and Plan of Merger among the Company, Capstone Sub Co. and Capstone Affluent Strategies, Inc., dated December 13, 2013		8-K	2.1	12/13/2013
2.3.1	Articles of Merger filed January 15, 2014, between Capstone Sub Co. and Capstone Affluent Strategies, Inc.		8-K	3(i)(d)	1/16/2014
2.3.2	Rescission of Agreement and Plan of Merger among the Company, Capstone Sub Co. and Capstone Affluent Strategies, Inc.		8-K	10.1	5/1/2014
3.1	Articles of Incorporation of Creative App Solutions, Inc. dated July 10, 2012		S-1	3(i)(a)	10/17/2012
3.1.1	Certificate of Amendment to Articles of Incorporation filed August 26, 2013		8-K	3(i)(a)	8/29/2013
3.1.2	Certificate of Change filed September 6, 2013		8-K	3(i)(c)	9/12/2013
3.2	Bylaws		S-1	3(ii)	10/17/2012
3.2.1	Amended Bylaws, adopted August 26, 2013		10-K	3.2.1	2/18/2015
31.1	Certification pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 – CEO	X
31.2	Certification pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 – CFO	X
32.1	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 – CEO	X
32.2	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 – CFO	X

-4336-

(table of contents)

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CAPSTONE FINANCIAL GROUP, INC.

By: /s/ Darin R. Pastor

Darin R. Pastor, Chief Executive Officer

Date: ~~June~~September 81, 2016

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Darin R. Pastor	Chairman of the Board of Directors,	~~June~~September 81, 2016
Darin R. Pastor	Chief Executive Officer (Principal Executive Officer)
/s/ Halford W. Johnson	Chief Financial Officer	~~June~~September 81, 2016
Halford W. Johnson	(Principal Financial Officer and Principal Accounting Officer)

-4437-

Filing Compare · CAPSTONE FINANCIAL GROUP, INC.